预约演示
更新于：2026-04-04
Omadacycline Tosylate
甲苯磺酸奥马环素
更新于：2026-04-04
概要
基本信息
药物类型 小分子化药 |
别名 Amadacycline、Neopentyl aminomethylminocycline、Omadacycline + [13] |
作用方式 抑制剂 |
作用机制 30S subunit抑制剂(30S核糖体亚基抑制剂) |
在研适应症 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (2018-10-02), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟)、快速通道 (美国) |
登录后查看时间轴
结构/序列
分子式C36H48N4O10S |
InChIKeySETFNHZTVGTBHC-XGLFQKEBSA-N |
CAS号1075240-43-5 |
关联
26
项与 甲苯磺酸奥马环素 相关的临床试验NCT06462326
A Phase 1, Randomized, Double-Blind Study to Compare the Effect of Omadacycline PO Versus Moxifloxacin PO on the Gut Microbiota in Healthy Adult Volunteers
This is a randomized (1:1), double-blind, double-dummy, phase I study to compare the effects of Omadacycline versus Moxifloxacin on gut microbiota and the resistomes in healthy adult volunteers.The study consists of 3 phases: Screening, double-blind treatment, and follow-up. Healthy volunteers aged 18-40 years, who meet entry criteria, are randomly assigned to a treatment group using an Interactive Voice Response System/Interactive Web Response System (IxRS) and receive the first dose of the study drug.
开始日期2024-04-16 |
申办/合作机构 |
NCT06162286
A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Moxifloxacin IV/PO for Treating Adult Subjects With Community-acquired Bacterial Pneumonia (CABP)
The primary objective of the study is to show that in Chinese adults with CABP, a course of IV/PO treatment with omadacycline has similar clinical efficacy as the with the comparator antibiotic, IV/PO moxifloxacin. The study is designed as a bridging study, to confirm the results of the pivotal global CABP trial in an ethnically different population of Chinese.
开始日期2023-11-17 |
申办/合作机构 |
NCT05753215
Omadacycline Versus Standard-of-Care Oral Antibiotic Treatment for Bone and Joint Infections: An Open-Label, Non- Inferiority, Randomized, Controlled Trial
The study design is a randomized, open-label, clinical trial of omadacycline vs Standard of Care (SOC) antibiotics for bone and join infection (BJI) treatment. Study participants will have their BJI regimen chosen by their treating physicians, (typically Infectious Diseases for hardware and prosthetic joint infections, or multidisciplinary Limb Salvage team for diabetic foot infections) prior to enrollment. Then participants will be randomized to an omadacycline-containing regimen versus the a priori chosen SOC regimen. Participants must require between 4 and 12 weeks of therapy for their BJI. The exact duration of therapy will be decided by the participants' treating physician. At 12 weeks, if the treating physician wishes to extend therapy, participants receiving omadacycline will be transitioned to other SOC antibiotics.
Once enrolled, participants will be followed via in-person clinic visits at the following intervals: weeks 0, 2, 4, 8, and 12. A final in-person visit will occur 2 weeks post-treatment completion. A phone survey will occur 3 months post-treatment completion. Participants in the SOC group will follow the same schedule.
Oral once-daily dosing options for S. aureus and Coagulase negative Staphylococcus are essentially non-existent. Thus, omadacycline possesses a novel and advantageous option for BJI treatment. Its convenient dosing regimen will almost certainly be associated with improved adherence, and higher adherence may, in turn, improve clinical outcome. Investigators hypothesize that omadacycline will be a well-tolerated and efficacious oral antibiotic for BJIs and will be associated with improved adherence compared with standard of care oral antibiotics. Investigators believe omadacycline addresses the unmet need for an oral antibiotic that is well-tolerated and efficacious for use as a prolonged therapy for BJIs. To this aim, investigators will perform a randomized, open-label clinical trial of omadacycline to SOC antibiotics for BJIs.
Once enrolled, participants will be followed via in-person clinic visits at the following intervals: weeks 0, 2, 4, 8, and 12. A final in-person visit will occur 2 weeks post-treatment completion. A phone survey will occur 3 months post-treatment completion. Participants in the SOC group will follow the same schedule.
Oral once-daily dosing options for S. aureus and Coagulase negative Staphylococcus are essentially non-existent. Thus, omadacycline possesses a novel and advantageous option for BJI treatment. Its convenient dosing regimen will almost certainly be associated with improved adherence, and higher adherence may, in turn, improve clinical outcome. Investigators hypothesize that omadacycline will be a well-tolerated and efficacious oral antibiotic for BJIs and will be associated with improved adherence compared with standard of care oral antibiotics. Investigators believe omadacycline addresses the unmet need for an oral antibiotic that is well-tolerated and efficacious for use as a prolonged therapy for BJIs. To this aim, investigators will perform a randomized, open-label clinical trial of omadacycline to SOC antibiotics for BJIs.
开始日期2023-05-09 |
申办/合作机构 |
100 项与 甲苯磺酸奥马环素 相关的临床结果
登录后查看更多信息
100 项与 甲苯磺酸奥马环素 相关的转化医学
登录后查看更多信息
100 项与 甲苯磺酸奥马环素 相关的专利（医药）
登录后查看更多信息
346
项与 甲苯磺酸奥马环素 相关的文献（医药）2026-02-02·Open Forum Infectious Diseases
Recovery and Stability of Omadacycline 150-mg Crushed Tablets Dispersed in Food or Water and Administered via Nasogastric Tube
Article
作者: Garey, Kevin W ; Huynh-Phan, Ricky ; Hu, Chenlin ; Eubank, Taryn A ; Rodriguez Robles, Kevin M
Abstract:
Background:
Omadacycline, an aminomethylcycline tetracycline available orally and intravenously, is approved for the treatment of patients with acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia, some of whom have difficulty swallowing tablets. The objective of this study was to assess the stability and recovery of crushed omadacycline 150-mg tablets.
Methods:
The recovery and stability of crushed omadacycline 150-mg tablets was assessed using 3 crushing methods (pill crusher, mortar/pestle, and sandwich bag method) and 3 dispersal products (water, vanilla syrup, or applesauce) over 24 hours at room temperature and administered via nasogastric tube. Omadacycline and its epimer (OMC-4-epimer) concentrations were assessed via liquid chromatography tandem mass spectrometry.
Results:
There was no significant difference in recovery of omadacycline or OMC-4-epimer proportion based on crushing technique. There were significantly higher proportions of OMC-4-epimer in applesauce experiments than in water or vanilla syrup experiments, regardless of crushing methods. All experiments had significantly less recovery of omadacycline and increased proportions of OMC-4-epimer at 24 hours compared with earlier time points. There was no significant difference in recovery of omadacycline or OMC-4-epimer proportion using either type of nasogastric tube with omadacycline recovery above 91%.
Conclusions:
The optimal method for recovery and stability of crushed omadacycline was to rinse the crushing device thoroughly into the collection container and disperse it into water, with consumption immediately or after no more than 4 hours. Vanilla syrup may be used as an alternative dispersal vehicle to be consumed immediately if used.
2026-01-19·JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
A disproportionality analysis of adverse events associated with omadacycline based on the FDA adverse event reporting system database
Article
作者: Qu, Jian ; Wang, Yi-Ming ; Zhao, Ye-Lei ; Qu, Qiang ; Zhang, Yan-Tao
Abstract:
Objective:
Omadacycline, a novel aminomethylcycline antibiotic for community-acquired bacterial infections, lacks comprehensive real-world safety data. We evaluated its adverse drug reactions (ADRs) using the FDA Adverse Event Reporting System (FAERS).
Methods:
A comprehensive analysis of post-marketing ADR reports submitted to FAERS between the first quarter of 2020 and the fourth quarter of 2024 was conducted. Disproportionality signals were assessed via four methods: reporting odds ratio (ROR), proportional reporting ratio, Bayesian confidence propagation neural network and multi-item gamma Poisson shrinker.
Results and conclusion:
Among 4541 omadacycline-related reports, 577 distinct ADRs were identified. The most frequently reported ADRs were nausea (221 cases, 14.1%), vomiting (129), diarrhoea (93), dyspnoea (56) and rash (52). The strongest safety signals (ROR) included tooth discolouration (ROR = 184.33, 95% CI = 96.79–351.06), tongue discolouration (159.88, 101.76–251.25) and Mycobacterium avium complex infection (73.30, 40.15–133.78). Hepatic events (e.g. elevated transaminases) and mortality (49 cases) also demonstrated significant signals. Omadacycline is associated with gastrointestinal disturbances, dental discolouration and respiratory complications. Vigilance for hepatic injury and mortality is warranted, especially in elderly comorbid patients. Ongoing pharmacovigilance integrating real-world evidence is essential.
2026-01-06·JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Omadacycline as a drug candidate for
Mycobacterium avium
infections:
in vitro
insights on single and combination therapies
Article
作者: De Steenwinkel, Jurriaan E M ; Meliefste, Henriëtte M ; Ammerman, Nicole C ; Klaassen, Corné H W ; Serio, Alisa W ; Mudde, Saskia E ; Pierce, Jessica V ; Bax, Hannelore I
Abstract:
Objectives:
The current antibiotic arsenal for the treatment of Mycobacterium avium infections is limited and new treatment options are needed. This exploratory study assessed the in vitro activity of omadacycline against M. avium alone and combined with current guideline-recommended antibiotics and the ability of omadacycline to prevent the emergence of antibiotic resistance.
Methods:
The activity of omadacycline and comparator antibiotics against M. avium was studied by minimum inhibitory concentration (MIC) assays and time-kill kinetics assays to investigate time- and concentration-dependent activity patterns. Omadacycline’s ability to prevent clarithromycin and amikacin resistance was investigated by phenotypic and molecular assays.
Results:
The MIC of omadacycline was impacted by medium composition: a higher MIC was found in CAMHB (128 mg/L) versus Middlebrook broth (8 mg/L). MIC values were also impacted by omadacycline instability in solution over time and daily drug supplementation reduced the MIC to 1 mg/L. In time-kill assays, omadacycline demonstrated time- and concentration-dependent activity. Omadacycline-containing drug combinations resulted in varying degrees of enhanced activity, which was most apparent for omadacycline plus amikacin. Omadacycline prevented amikacin MICs from increasing and impeded the emergence of rrs mutations observed with amikacin alone. While enhanced activity of omadacycline plus clarithromycin was less pronounced, rrl mutations were not detected in the presence of omadacycline.
Conclusions:
Omadacycline demonstrated in vitro activity against M. avium, particularly in combination with amikacin. Emergence of clarithromycin and amikacin resistance seemed to be prevented by co-exposure to omadacycline. Further research is warranted to assess omadacycline’s role in treating M. avium disease.
331
项与 甲苯磺酸奥马环素 相关的新闻（医药）2026-04-03
Journal of Antimicrobial Chemotherapy Volume 81, Issue 1抗菌化疗杂志81卷 1期
https://academic.oup.com/jac/issue
50th Anniversary Collection
50周年纪念合集
Review（综述）
1
Artificial intelligence for improving decision-making in bacterial infection management: a narrative review
人工智能在改善细菌感染治疗决策中的应用：一项叙述性综述
Anisia Talianu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf470, https://doi.org/10.1093/jac/dkaf470
Reviews（综述）
2
Evolving landscape of methicillin-resistant Staphylococcus pseudintermedius: the emergence of new epidemic waves across Europe, Asia and North America
耐甲氧西林中间型葡萄球菌的演变格局：欧洲、亚洲和北美洲新流行浪潮的出现
Lillian Rose Giarratana and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf340, https://doi.org/10.1093/jac/dkaf340
3
Azithromycin resistance in non-typhoidal Salmonella: a review
非伤寒沙门氏菌对阿奇霉素的耐药性：综述
Zhe Zhu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf341, https://doi.org/10.1093/jac/dkaf341
4
Antibiotic pharmacodynamics: from MIC to advanced metrics and their applications
抗生素药效动力学：从最低抑菌浓度到高级指标及其应用
Malin Andersson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf374, https://doi.org/10.1093/jac/dkaf374
5
Progress in the study of drug resistance mechanism of Bacillus cereus
蜡样芽孢杆菌耐药机制研究进展
Yuhang Zhang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf399, https://doi.org/10.1093/jac/dkaf399
6
The curious constraints on clofazimine
氯法齐明的奇特限制
Maple Goh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf430, https://doi.org/10.1093/jac/dkaf430
7
Antiplasmid systems: a novel strategy to combat antibiotic resistance
抗质粒系统：对抗抗生素耐药性的新策略
Mohd Asim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf472, https://doi.org/10.1093/jac/dkaf472
Systematic Review（系统综述）
8
Coccidioidomycosis in Europe: a systematic literature review of epidemiology, treatment and outcomes
欧洲球孢子菌病：流行病学、治疗和预后的系统文献综述
Priya Shastri and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf407, https://doi.org/10.1093/jac/dkaf407
9
Systematic review of antimicrobial pharmacokinetic/pharmacodynamic indices in murine thigh and hollow fibre dose fractionation studies analysed with a standard method
用标准方法分析小鼠大腿和空心纤维剂量分次研究中的抗菌药物药代动力学/药效动力学指数的系统综述
Najla Alabdulkarim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf446, https://doi.org/10.1093/jac/dkaf446
Virtual Roundtable（虚拟圆桌会议）
10
Procalcitonin in the management of lower respiratory tract infection and sepsis
降钙素原在下呼吸道感染和败血症治疗中的应用
Ramy H Elshaboury and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf298, https://doi.org/10.1093/jac/dkaf298
Original Research（论著）
11
Model-based assessment of letermovir pharmacokinetics in allogeneic haematopoietic stem cell transplant recipients
来特莫韦在异基因造血干细胞移植受者中药代动力学的基于模型的评估
Chrisoula Tahtsidou and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf427, https://doi.org/10.1093/jac/dkaf427
12
In vitro exebacase (CF-301) activity against methicillin-susceptible or methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci strains isolated from patients with infective endocarditis
体外试验评估依拉环素（CF-301）对甲氧西林敏感或甲氧西林耐药金黄色葡萄球菌及凝固酶阴性葡萄球菌（从感染性心内膜炎患者中分离）的活性
María-Alexandra Cañas and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf435, https://doi.org/10.1093/jac/dkaf435
13
Evaluation of subcutaneous amoxicillin/clavulanic acid pharmacokinetics as an alternative to the intravenous route in older patients—the PhASAge Study
评估皮下注射阿莫西林/克拉维酸药代动力学作为老年患者静脉给药替代方案——PhASAge研究
Nicolas Grégoire and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf381, https://doi.org/10.1093/jac/dkaf381
14
Real-life use of isavuconazole in Spanish children and adolescents
西班牙儿童和青少年中艾沙康唑的实际使用情况
Natalia Mendoza-Palomar and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf394, https://doi.org/10.1093/jac/dkaf394
15
No pharmacovigilance signal of intracranial hypertension associated with glycylcyclines: a FAERS-based disproportionality analysis
基于FAERS数据库的不成比例性分析：未发现甘氨酰环素类与颅内高压相关的药物警戒信号
Slobodan M Jankovic and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf395, https://doi.org/10.1093/jac/dkaf395
16
Posaconazole enteral tube administration in adults: pharmacokinetic target attainment of oral suspension compared with crushed delayed-release tablet
成人经肠内营养管给予泊沙康唑：口服混悬液与碾碎的缓释片的药代动力学目标达成情况比较
Nirjan Bhattarai and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf396, https://doi.org/10.1093/jac/dkaf396
17
Characterizing CYP3A4-mediated drug interactions: a fixed-sequence pharmacokinetic Chinese study of posaconazole and ruxolitinib in haematological malignancies
CYP3A4介导的药物相互作用特征：一项关于泊沙康唑和鲁索替尼在血液系统恶性肿瘤中的固定序列药代动力学中国研究
Beibei Liang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf398, https://doi.org/10.1093/jac/dkaf398
18
Differences in prescription for impetigo and cellulitis across years in three European countries
三个欧洲国家不同年份脓疱病和蜂窝织炎的处方差异
Thomas Bettuzzi and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf400, https://doi.org/10.1093/jac/dkaf400
19
β-Lactam concentrations monitored in the early phase of community-acquired sepsis in the intensive care unit
重症监护室社区获得性脓毒症早期阶段监测的β-内酰胺浓度
Karolina Liljedahl Prytz and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf401, https://doi.org/10.1093/jac/dkaf401
20
Enhanced antimycobacterial efficacy of simulated inhaled clofazimine versus oral clofazimine in combination with azithromycin and ethambutol in a hollow-fiber system
在空心纤维系统中，模拟吸入氯法齐明与口服氯法齐明联合阿奇霉素和乙胺丁醇的抗结核分枝杆菌疗效增强比较
Jelmer Raaijmakers and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf402, https://doi.org/10.1093/jac/dkaf402
21
Identification of antimicrobial resistance genes in Escherichia coli through network diffusion
通过网络扩散法鉴定大肠杆菌中的抗生素耐药基因
Anis Mansouri and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf404, https://doi.org/10.1093/jac/dkaf404
22
Preclinical evaluation of epetraborole in the hollow fibre system model of Mycobacterium abscessus lung disease
依培硼罗在脓肿分枝杆菌肺病空心纤维系统模型中的临床前评估
Sanjay Singh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf405, https://doi.org/10.1093/jac/dkaf405
23
The β-lactamase inhibitor concentration-dependent minimum inhibitory concentration (MICcBLI) as methodology to assess the pharmacokinetic/pharmacodynamic relationship of piperacillin/tazobactam for dosing optimization
β-内酰胺酶抑制剂浓度依赖性最低抑菌浓度（MICcBLI）作为评估哌拉西林/他唑巴坦药代动力学/药效动力学关系以优化给药的方法
Malin Andersson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf406, https://doi.org/10.1093/jac/dkaf406
24
Unravelling the triad of penicillin-binding proteins, β-lactamase activity, and mRNA dynamics in Pseudomonas aeruginosa AmpC induction
解析铜绿假单胞菌AmpC诱导过程中青霉素结合蛋白、β-内酰胺酶活性和mRNA动态的三元关系
Maria Montaner and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf408, https://doi.org/10.1093/jac/dkaf408
25
Unnoticed spread of linear VanA-plasmids in vancomycin-variable Enterococcus faecium strains across different regions: a diagnostics challenge
不同地区万古霉素可变型粪肠球菌菌株中线性VanA质粒的未被察觉的传播：一项诊断挑战
Ana C Almeida-Santos and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf409, https://doi.org/10.1093/jac/dkaf409
26
Switching from etravirine to doravirine in virologically suppressed people with HIV: results from the French multicentre SWEED observational study
在病毒学抑制的HIV感染者中从依曲韦林切换至多拉韦林：法国多中心SWEED观察性研究的结果
Romain Palich and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf410, https://doi.org/10.1093/jac/dkaf410
27
HIV-1 drug resistance among pregnant and breastfeeding mothers and its association with paediatric HIV infections in the Dolutegravir era in Uganda
乌干达多替拉韦时代孕产妇及哺乳期母亲中HIV-1耐药情况及其与儿童HIV感染的关联
Anne Kapaata and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf411, https://doi.org/10.1093/jac/dkaf411
28
Outpatient antibiotic prescribing for medically attended respiratory syncytial virus, influenza, or human metapneumovirus illness among high-risk adults in rural Wisconsin, United States
美国威斯康星州农村地区高风险成人因呼吸道合胞病毒、流感或人偏肺病毒感染就诊时的门诊抗生素处方情况
Sarah C J Jorgensen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf412, https://doi.org/10.1093/jac/dkaf412
29
Omadacycline as a drug candidate for Mycobacterium avium infections: in vitro insights on single and combination therapies
奥马环素作为鸟分枝杆菌感染候选药物：单药及联合治疗的体外研究
Saskia E Mudde and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf413, https://doi.org/10.1093/jac/dkaf413
30
Post-pandemic trends in Streptococcus pneumoniae serotype epidemiology and antibiotic susceptibility in adults with invasive and non-invasive pneumococcal disease in the USA (2022–2023)
后疫情时代美国成人侵袭性与非侵袭性肺炎链球菌病血清型流行病学及抗生素敏感性趋势（2022-2023）
Mekki F Bensaci and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf414, https://doi.org/10.1093/jac/dkaf414
31
Benznidazole pharmacokinetics in patients with chronic Chagas disease: association with demographic factors and adverse drug reactions
慢性恰加斯病患者苯芴醇药代动力学：与人口统计学因素及药物不良反应的关联
Gabriel P E Silveira and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf416, https://doi.org/10.1093/jac/dkaf416
32
Acquired antimicrobial resistance genes in Bordetella Species: a global genomic analysis
博德特氏菌属中获得的抗菌药物耐药基因：全球基因组分析
Biao Tang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf418, https://doi.org/10.1093/jac/dkaf418
33
Machine learning for personalized antimicrobial susceptibility breakpoints: (Adaptive clinical breakpoint interpretation)
基于机器学习的个性化抗菌药物敏感性折点制定（自适应临床折点解释）
Yinzheng Zhong and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf419, https://doi.org/10.1093/jac/dkaf419
34
Multicentre investigation of Wickerhamomyces anomalus fungemia in India: emerging resistance and mechanistic insights
印度异常威克汉姆酵母菌血症的多中心研究：新发耐药性及机制洞察
Shristi Verma and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf420, https://doi.org/10.1093/jac/dkaf420
35
Reducing aztreonam/avibactam waste: insights from Monte Carlo simulations
减少氨曲南/阿维巴坦浪费：蒙特卡洛模拟的启示
Yeleen Fromage and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf421, https://doi.org/10.1093/jac/dkaf421
36
Nanoparticle-based co-delivery of ciprofloxacin and meropenem enhances synergistic activity against multidrug-resistant hypervirulent Klebsiella pneumoniae clinical isolates
基于纳米颗粒的环丙沙星与美罗培南共递送可增强对多重耐药高毒力肺炎克雷伯菌临床分离株的协同活性
Reham Mostafa and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf422, https://doi.org/10.1093/jac/dkaf422
37
Development of population pharmacokinetic models of total and free piperacillin in critically ill children and young adults for Monte Carlo simulations and model-informed precision dosing
危重症儿童及青年总游离哌拉西林群体药代动力学模型开发：用于蒙特卡洛模拟及模型引导的精准给药
Sonya Tang Girdwood and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf423, https://doi.org/10.1093/jac/dkaf423
38
Reaching the target: time and dose required to achieve target vancomycin plasma concentrations in admitted patients
达标分析：住院患者达到目标万古霉素血浆浓度所需的时间与剂量
W Töpfer and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf424, https://doi.org/10.1093/jac/dkaf424
39
Notable transmitted HIV drug resistance among people who inject drugs in Pakistan
巴基斯坦注射毒品人群中显著传播的HIV耐药性
Stephanie Melnychuk and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf425, https://doi.org/10.1093/jac/dkaf425
40
Synergistic but clinically unattainable: amoxicillin/ceftriaxone combination against ampicillin-susceptible Enterococcus faecium
协同但临床难以实现：阿莫西林/头孢曲松联合对氨苄西林敏感粪肠球菌的体外活性
Ahmed Ashrin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf426, https://doi.org/10.1093/jac/dkaf426
41
Pharmacodynamic studies of taniborbactam (VNRX-5133) combined with cefepime against β-lactamase–producing Gram-negative bacteria in a neutropenic murine thigh infection model
中性粒细胞减少小鼠大腿感染模型中他尼硼巴坦（VNRX-5133）联合头孢吡肟对产β-内酰胺酶革兰氏阴性菌的药效动力学研究
Panagiota-Christina Georgiou and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf431, https://doi.org/10.1093/jac/dkaf431
42
Epidemiology and treatment of endocarditis secondary to Enterobacterales other than Serratia spp.
非塞拉蒂亚属肠杆菌目细菌所致心内膜炎的流行病学及治疗
Clayton F Hausberger and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf432, https://doi.org/10.1093/jac/dkaf432
43
Enhanced activity of apramycin and apramycin-based combinations against Mycobacteroides abscessus
阿普拉霉素及其组合对脓肿分枝杆菌的增强活性
Yanqin Huang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf433, https://doi.org/10.1093/jac/dkaf433
44
Efflux-mediated multidrug resistance mechanism in Trichophyton indotineae and Trichophyton rubrum; role of ABC transporters and MFS gene
印度毛癣菌与红色毛癣菌中由ABC转运蛋白和MFS基因介导的流出泵型多重耐药机制
Dipika Shaw and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf434, https://doi.org/10.1093/jac/dkaf434
45
Sphingobacterium spp. as intrinsic producers of SPI Ambler class B metallo-β-lactamases
鞘氨醇杆菌属作为SPI Ambler B类金属β-内酰胺酶的固有产生者
Delphine Girlich and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf436, https://doi.org/10.1093/jac/dkaf436
46
Global phylogeography and genomic characterization of blaNDM-1-positive carbapenem-resistant Acinetobacter soli
blaNDM-1阳性碳青霉烯耐药溶胶阿卡净菌的全球系统发育地理学及基因组特征
Pengpeng Min and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf437, https://doi.org/10.1093/jac/dkaf437
47
Pharmacokinetics and tolerability of one-month daily rifapentine for latent tuberculosis treatment in haemodialysis patients
血液透析患者潜伏性结核治疗中每月一次每日利福喷丁的药代动力学及耐受性
Thornthun Ueaphongsukkit and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf439, https://doi.org/10.1093/jac/dkaf439
48
In vitro susceptibility of cefepime-enmetazobactam, cefepime-taniborbactam and cefepime-zidebactam towards carbapenemase-producing Enterobacterales
头孢吡肟-恩美他唑巴坦、头孢吡肟-他尼硼巴坦及头孢吡肟-齐德巴坦对产碳青霉烯酶肠杆菌目的体外敏感性
Marion Dutkiewicz and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf440, https://doi.org/10.1093/jac/dkaf440
49
In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates
舒巴坦/杜洛巴坦联合β-内酰胺类抗生素对澳大利亚脓肿分枝杆菌分离株的体外疗效
Kirby Patterson-Fahy and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf441, https://doi.org/10.1093/jac/dkaf441
50
Harnessing CRISPR–Cas9 and CRISPRi systems to reverse antibiotic resistance in a clinical multidrug-resistant Escherichia coli isolate
利用CRISPR-Cas9及CRISPRi系统逆转临床多重耐药大肠杆菌分离株的抗生素耐药性
Ruonan Zhao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf442, https://doi.org/10.1093/jac/dkaf442
51
Cotrimoxazole in the intensive care unit: an impossible task for the fixed association in real life?
重症监护室中复方磺胺甲噁唑的应用：固定组合在现实中的不可行性？
Manon Launay and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf443, https://doi.org/10.1093/jac/dkaf443
52
National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing
哥伦比亚全国代表性调查：基于下一代测序的抗逆转录病毒耐药相关突变分析
Ernesto Martínez-Buitrago and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf444, https://doi.org/10.1093/jac/dkaf444
53
A model-based comparison of dose reduction strategies for fixed-dose dolutegravir-containing regimens
基于模型的含固定剂量多替拉韦方案减量策略比较
Laura Dickinson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf445, https://doi.org/10.1093/jac/dkaf445
54
Therapeutic drug monitoring and target attainment of unbound flucloxacillin in hospitalized patients with measured MICs (FLUTE)
住院患者中游离氟氯西林的治疗药物监测及目标达成情况（基于实测最低抑菌浓度的FLUTE研究）
Pjotr P Temme and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf447, https://doi.org/10.1093/jac/dkaf447
55
Nirmatrelvir-ritonavir addition to acute care formulary: a retrospective, multi-centre evaluation of quantitative economic and qualitative clinical outcomes
奈玛特韦/利托那韦纳入急症治疗目录：一项多中心回顾性评估定量经济与定性临床结果的研究
Jose Valdes Ledesma and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf448, https://doi.org/10.1093/jac/dkaf448
56
Local antibiotic resistance surveillance in nursing homes using lot quality assurance sampling: a feasibility study
采用批量质量保证抽样法对养老院进行本地抗生素耐药性监测的可行性研究
Sacha Kuil and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf451, https://doi.org/10.1093/jac/dkaf451
57
High in vitro activity of the novel antimicrobial gepotidacin against Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021–24
2021-2024年，在世卫组织三个区域的八个世卫组织增强淋球菌抗菌药物监测计划国家中，新型抗菌药物吉皮达星对淋病奈瑟菌分离株的体外活性较高
Josefine Ahlstrand and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf452, https://doi.org/10.1093/jac/dkaf452
58
Despite increasing use of integrase inhibitors to treat HIV infection, resistance to this class remains stable
尽管整合酶抑制剂用于治疗HIV感染的使用量不断增加，但此类药物的耐药性仍保持稳定
Cathia Soulie and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf454, https://doi.org/10.1093/jac/dkaf454
59
Fine-needle aspiration in infected necrotizing pancreatitis in the delayed intervention era: a post hoc analysis of safety, microbiological yield and therapeutic implications
延迟干预时代感染性坏死性胰腺炎的细针穿刺抽吸术：安全性、微生物学检出率及治疗意义的事后分析
Hannah S Pauw and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf455, https://doi.org/10.1093/jac/dkaf455
60
β-Lactam dosing in critically ill children: predictors for target non-attainment
危重症儿童β-内酰胺类药物给药：未达目标浓度的预测因素
Stef Schouwenburg and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf457, https://doi.org/10.1093/jac/dkaf457
61
Co-administration of triazoles with calcineurin or mammalian target of rapamycin inhibitors in solid organ transplant patients hospitalized with invasive aspergillosis
实体器官移植患者合并侵袭性曲霉病住院时三唑类药物与钙调磷酸酶抑制剂或哺乳动物雷帕霉素靶蛋白抑制剂的联合用药情况
Barbara Alexander and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf461, https://doi.org/10.1093/jac/dkaf461
62
In vitro selection of cefiderocol-resistant mutants in Acinetobacter baumannii harbouring the most common carbapenemase genes
携带最常见碳青霉烯酶基因的鲍曼不动杆菌中头孢地尔耐药突变体的体外筛选
Otávio Hallal Ferreira Raro and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf462, https://doi.org/10.1093/jac/dkaf462
63
Preventing resistance development in infections by OXA β-lactamase-producing Pseudomonas aeruginosa: correlating clinical outcomes with hollow-fibre model input
预防产OXA β-内酰胺酶铜绿假单胞菌感染耐药性的产生：将临床结局与中空纤维模型输入相关联
María M Montero and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf464, https://doi.org/10.1093/jac/dkaf464
64
A national pilot community pharmacy–led urinary tract infection service: clinical and patient-reported outcomes from 9077 consultations
全国社区药房主导的尿路感染服务试点项目：9077次咨询的临床结局和患者报告结局
Efi Mantzourani and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf466, https://doi.org/10.1093/jac/dkaf466
65
Towards enhanced translational value: preclinical drug activity testing against actively multiplying, nutrient-starved and pellicle biofilm-embedded Mycobacterium abscessus
提高转化价值：针对活跃增殖、营养匮乏和生物膜包裹的脓肿分枝杆菌进行临床前药物活性测试
Henriëtte M Meliefste and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf468, https://doi.org/10.1093/jac/dkaf468
Research Letters（研究快报）
66
Novel multiresistance transposon Tn7731 in bovine Pasteurella multocida from Germany
德国牛源多杀性巴氏杆菌中新型多重耐药转座子Tn7731
Henrike Krüger-Haker and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf336, https://doi.org/10.1093/jac/dkaf336
67
Efficacy of eravacycline in difficult-to-treat (DTR) Acinetobacter baumannii bacteraemia in ICU: a case report
厄他培南治疗重症监护病房难治性鲍曼不动杆菌菌血症的疗效：一例病例报告
Monica Melchio and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf347, https://doi.org/10.1093/jac/dkaf347
68
Possible increased risk of Epstein–Barr virus (EBV) infection and post-transplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients
来特莫韦暴露的造血细胞移植受者中EB病毒感染和移植后淋巴增殖性疾病风险可能增加
Jose F Camargo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf348, https://doi.org/10.1093/jac/dkaf348
69
Dalbavancin dosing in a severely underweight woman with prosthetic valve endocarditis: the critical role of proactive therapeutic drug monitoring
达巴万星在严重体重不足人工瓣膜心内膜炎女性患者中的给药：主动治疗药物监测的关键作用
Ambra Barco and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf365, https://doi.org/10.1093/jac/dkaf365
70
Cefazolin-induced seizures in a haemodialysis patient with elevated serum and cerebrospinal fluid concentrations: a case report
血液透析患者头孢唑林血清和脑脊液浓度升高诱发癫痫：一例病例报告
Kohei Hasegawa and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf373, https://doi.org/10.1093/jac/dkaf373
71
Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes
使用聚丙烯腈膜进行连续性肾脏替代治疗的患者中卡泊芬净药代动力学治疗监测的回顾性分析
Antoine Hérault and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf390, https://doi.org/10.1093/jac/dkaf390
72
Diffusion of OXA-48- and NDM-5-producing Klebsiella pneumoniae ST383 clone in Central Italy
产OXA-48和NDM-5的肺炎克雷伯菌ST383克隆在意大利中部的传播
Gloria D’Achille and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf397, https://doi.org/10.1093/jac/dkaf397
73
Durability of lenacapavir in viremic heavily treatment-experienced people with HIV: real-world data from the PRESTIGIO Registry
来那卡帕韦在病毒载量阳性且接受过大量抗逆转录病毒治疗的HIV感染者中的持久性：来自PRESTIGIO登记处的现实数据
Tommaso Clemente and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf415, https://doi.org/10.1093/jac/dkaf415
74
Co-carriage of the oxazolidinone resistance genes cfr and optrA in a linezolid-resistant Staphylococcus rostri isolate from a pig-farm worker
猪场工人利奈唑胺耐药猪鼻支原体分离株中噁唑烷酮类耐药基因cfr和optrA的共携带情况
Gi Yong Lee and Soo-Jin Yang
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf428, https://doi.org/10.1093/jac/dkaf428
75
Importance of reviewing the package insert from gradient strip manufacturers
梯度扩散法药敏纸片生产商说明书审阅的重要性
Mandy Wootton and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf429, https://doi.org/10.1093/jac/dkaf429
76
One resistance gene, many transposons: repeated formation of compound and pseudo-compound transposons carrying the aphA1 kanamycin and neomycin resistance gene
一个耐药基因，多个转座子：携带aphA1卡那霉素和新霉素耐药基因的复合及假复合转座子的重复形成
Christopher J Harmer and Ruth M Hall
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf450, https://doi.org/10.1093/jac/dkaf450
77
Absence of lymphogranuloma venereum among men who have sex with men on PrEP receiving doxycycline postexposure prophylaxis
接受暴露后多西环素预防性治疗的暴露前预防用药男男性行为者中未发现性病淋巴肉芽肿
Cristina Gómez-Ayerbe and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf456, https://doi.org/10.1093/jac/dkaf456
78
In vitro activity of gepotidacin against Chlamydia trachomatis
吉皮达星对沙眼衣原体的体外活性
Arabella Touati and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf460, https://doi.org/10.1093/jac/dkaf460
Journal of Antimicrobial Chemotherapy Volume 81, Issue 2抗菌化疗杂志 81卷 2期
https://academic.oup.com/jac/issue
Viewpoints（观点）
1
Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome?
长效糖肽类：最需要它们的患者获取药物的障碍有哪些，如何克服？
Aleece MacPhail and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf471, https://doi.org/10.1093/jac/dkaf471
2
Redefining antifungal prophylaxis in acute leukaemia in the era of targeted therapies
靶向治疗时代急性白血病抗真菌预防的重新定义
Marcio Nucci and Johan Maertens
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag010, https://doi.org/10.1093/jac/dkag010
Reviews（综述）
3
Research progress on resistance mechanisms and clinical efficacy of tigecycline against Klebsiella pneumoniae
替加环素对肺炎克雷伯菌的耐药机制及临床疗效研究进展
Meilin Wu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf504, https://doi.org/10.1093/jac/dkaf504
4
Liposomal amphotericin B and renal safety: review of the evidence and clinical considerations
两性霉素B脂质体与肾脏安全性：证据回顾及临床考量
Johan Maertens and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf473, https://doi.org/10.1093/jac/dkaf473
5
Strategies for mitigating severe COVID-19 in patients with haematological malignancy during the omicron era
奥密克戎时代减轻血液系统恶性肿瘤患者严重新冠肺炎的策略
Keiji Okinaka and Joshua T Schiffer
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf489, https://doi.org/10.1093/jac/dkaf489
Systematic Reviews（系统综述）
6
Safety and efficacy of gepotidacin in urinary tract infection: a GRADE-assessed systematic review and meta-analysis
吉泊替达辛治疗尿路感染的安全性和有效性：一项基于GRADE评估的系统综述和荟萃分析
Taha Ibrahim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf469, https://doi.org/10.1093/jac/dkaf469
7
The emerging clinical relevance and antimicrobial resistance of Pluralibacter gergoviae: a systematic review
产吲哚金黄杆菌日益凸显的临床相关性和抗菌药物耐药性：一项系统综述
Bruna Abdul Ahad Saad and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf476, https://doi.org/10.1093/jac/dkaf476
8
A comprehensive analysis of the mutational landscape determining polymyxin resistance in Klebsiella pneumoniae
决定肺炎克雷伯菌多粘菌素耐药性的突变谱综合分析
Sambit Kumar Dwibedy and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf503, https://doi.org/10.1093/jac/dkaf503
9
Factors promoting or hindering self-administered outpatient parenteral antimicrobial therapy: a systematic literature review
促进或阻碍自我给药门诊静脉注射抗菌药物治疗的因素：一项系统文献综述
Hester H Stoorvogel and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf490, https://doi.org/10.1093/jac/dkaf490
Original Research（论著）
10
Cefepime/enmetazobactam for Gram-negative periprosthetic joint infections? A randomized porcine study on target tissue pharmacokinetics
头孢吡肟/恩美唑巴坦治疗革兰氏阴性假体周围关节感染？一项关于猪的靶组织药代动力学的随机研究
M B D Nielsen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf487, https://doi.org/10.1093/jac/dkaf487
11
Impact of extracorporeal membrane oxygenation modes on voriconazole exposure in critically ill patients
体外膜肺氧合模式对危重患者伏立康唑暴露的影响
Xinrui Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf501, https://doi.org/10.1093/jac/dkaf501
12
Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic -pharmacodynamic modelling in adults and infants
基于模型通过成人和婴儿群体药代动力学-药效学模型评估VRC07-523LS在婴儿中的给药方案
Dustin Huynh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf449, https://doi.org/10.1093/jac/dkaf449
13
Antibiotic resistance of Pseudomonas aeruginosa strains—intracellular metabolomics analysis
铜绿假单胞菌菌株的抗生素耐药性——细胞内代谢组学分析
Karolina Anna Mielko-Niziałek and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf453, https://doi.org/10.1093/jac/dkaf453
14
In vitro activity of cefepime/zidebactam against sulbactam/durlobactam-susceptible and -resistant Acinetobacter baumannii clinical isolates
头孢吡肟/齐多巴坦对舒巴坦/杜洛巴坦敏感和耐药鲍曼不动杆菌临床分离株的体外活性
Carlo Tascini and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf467, https://doi.org/10.1093/jac/dkaf467
15
Prevalence of macrolide resistance in Mycoplasma pneumoniae in The Netherlands
荷兰肺炎支原体大环内酯类抗生素耐药性的流行情况
Patrick D J Sturm and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf475, https://doi.org/10.1093/jac/dkaf475
16
Simulated lung exposure in pneumonia patients to evaluate the antibacterial capacity and resistance suppression of clinical tigecycline regimens against carbapenem-resistant
Acinetobacter baumannii
模拟肺炎患者肺部暴露情况以评估临床替加环素方案对碳青霉烯类耐药鲍曼不动杆菌的抗菌能力和耐药抑制作用
Xiaonan Zhang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf477, https://doi.org/10.1093/jac/dkaf477
17
Enterococcus faecium harbouring vanA, optrA and cfr(D) on a linear plasmid in Canada: a CANWARD surveillance case
加拿大发现携带vanA、optrA和cfr(D)的粪肠球菌线性质粒：一项CANWARD监测病例
Melissa McCracken and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf478, https://doi.org/10.1093/jac/dkaf478
18
The effect of intrauterine exposure to aminoglycosides on neonatal hearing
宫内暴露于氨基糖苷类抗生素对新生儿听力的影响
Daniel Leshin-Carmel and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf483, https://doi.org/10.1093/jac/dkaf483
19
Ceftazidime/avibactam: a potent arsenal against multidrug-resistant Pseudomonas aeruginosa-unveiling in vitro and in vivo strategies
头孢他啶/阿维巴坦：对抗多重耐药铜绿假单胞菌的有力武器——揭示体内外策略
Jiaju Zhuo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf495, https://doi.org/10.1093/jac/dkaf495
20
Comparison of disk diffusion, MIC test strip and broth microdilution for eravacycline susceptibility testing of 422 Staphylococcus aureus isolates using ChinaCAST breakpoints
采用中国CAST折点，比较422株金黄色葡萄球菌对依拉环素的纸片扩散法、最低抑菌浓度测试条法和肉汤微量稀释法的敏感性测试结果
Xinying Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf502, https://doi.org/10.1093/jac/dkaf502
21
Penetration of daptomycin in cerebrospinal fluid during pneumococcal meningitis
肺炎链球菌性脑膜炎期间达托霉素在脑脊液中的渗透情况
Pascal Chavanet and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf474, https://doi.org/10.1093/jac/dkaf474
22
Rapid molecular diagnostics for detection of extensively drug-resistant Salmonella Typhi
用于检测广泛耐药伤寒沙门菌的快速分子诊断技术
Emma L Sweeney and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf481, https://doi.org/10.1093/jac/dkaf481
23
Gender inequality and antibiotic consumption: analysis of pharmaceutical sales data from 70 countries, 2000–22
性别不平等与抗生素消费：基于2000 - 2022年70个国家药品销售数据的分析
Deepshikha Batheja and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag002, https://doi.org/10.1093/jac/dkag002
24
Real-world evaluation of isavuconazole in children with cancer
伊沙康唑在儿童癌症患者中的现实应用评估
Janine Nijhuis and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf485, https://doi.org/10.1093/jac/dkaf485
25
Assessing antimicrobial susceptibility testing guideline adherence by laboratories providing bacteriology services in Ghana: a pilot study
加纳提供细菌学服务的实验室对抗菌药物敏感性试验指南依从性的评估：一项试点研究
Joseph Elikem Efui Acolatse and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag003, https://doi.org/10.1093/jac/dkag003
26
Resistance to second-generation integrase inhibitors in people with HIV following treatment failure on dolutegravir- or bictegravir-based ART in Taiwan
台湾地区基于多替拉韦或比克替拉韦的抗逆转录病毒治疗失败后，HIV感染者对第二代整合酶抑制剂的耐药性
Guan-Jhou Chen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf488, https://doi.org/10.1093/jac/dkaf488
27
In vitro activity of gepotidacin against a challenging panel of multidrug-resistant Neisseria gonorrhoeae isolates
吉泊西汀对一组具有挑战性的多重耐药淋病奈瑟菌分离株的体外活性
Michelle Jayne Cole and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag001, https://doi.org/10.1093/jac/dkag001
28
A disproportionality analysis of adverse events associated with omadacycline based on the FDA adverse event reporting system database
基于美国食品药品监督管理局（FDA）不良事件报告系统数据库的奥马环素相关不良事件比例失衡分析
Ye-Lei Zhao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag006, https://doi.org/10.1093/jac/dkag006
29
Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis
基于体重范围的口服异速缩放米替福新给药方案在儿童内脏利什曼病患者中的简化应用
Andres Mazariegos Herrera and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag014, https://doi.org/10.1093/jac/dkag014
30
evelopment of a capability framework for antimicrobial stewardship specialist health professionals working in the NHS in England: utilizing Delphi methodology
运用德尔菲法为在英国国家医疗服务体系（NHS）中工作的抗菌药物管理专业人员制定能力框架
Ryan A Hamilton and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf438, https://doi.org/10.1093/jac/dkaf438
31
First characterization of insertions in the HIV-1 integrase-coding region from people with HIV
首次对来自艾滋病病毒感染者的HIV-1整合酶编码区插入情况进行特征分析
Nhat Quang Tu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf491, https://doi.org/10.1093/jac/dkaf491
32
Development of an impedance-based fast antimicrobial susceptibility test for Neisseria gonorrhoeae
开发一种基于阻抗的淋病奈瑟菌快速抗菌药物敏感性检测方法
Caitlin N Daniels and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf493, https://doi.org/10.1093/jac/dkaf493
33
Juvenile toxicity and developmental safety of Zintrodiazine, a novel antimalarial candidate, in Wistar rats
新型抗疟候选药物Zintrodiazine在Wistar大鼠中的幼年毒性和发育安全性研究
Hitesh A Kadu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag008, https://doi.org/10.1093/jac/dkag008
34
Do the redefined EUCAST susceptibility categories warrant adjustment of paediatric antibiotic dosages? Pragmatic physiologically based pharmacokinetic modelling of four commonly used agents
欧洲抗微生物药物敏感性试验委员会（EUCAST）重新定义的敏感性分类是否需要调整儿童抗生素剂量？——对四种常用药物的实用生理药代动力学建模研究
Marika A de Hoop-Sommen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf463, https://doi.org/10.1093/jac/dkaf463
35
Exploring the opportunity for therapeutic drug monitoring (TDM) and precision dose antimicrobials in an outpatient antimicrobial therapy (OPAT) service: a prospective observational study
门诊抗菌治疗（OPAT）服务中开展治疗药物监测（TDM）和精准剂量抗菌治疗的机遇：一项前瞻性观察研究
R C Wilson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf484, https://doi.org/10.1093/jac/dkaf484
36
Impact of sex, age and body composition on rilpivirine and cabotegravir trough concentrations in people with HIV receiving long-acting injectable antiretroviral therapy
性别、年龄和身体成分对接受长效注射用抗逆转录病毒治疗的HIV感染者利匹韦林和卡博特韦谷浓度的影响
Maria Vittoria Cossu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag024, https://doi.org/10.1093/jac/dkag024
37
Pharmacokinetics of cefiderocol during prolonged intermittent kidney replacement therapy in two patients with septic shock
头孢地尔在两例感染性休克患者长时间间歇性肾脏替代治疗期间的药代动力学
Julius J Schmidt and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf496, https://doi.org/10.1093/jac/dkaf496
38
Understanding mechanisms of reduced cefiderocol susceptibility in pvdS and fecI mutants of Pseudomonas aeruginosa
了解铜绿假单胞菌pvdS和fecI突变体对头孢地尔敏感性降低的机制
Yoshinori Yamano and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag004, https://doi.org/10.1093/jac/dkag004
39
Biomarker-informed PBPK modelling of meropenem in paediatric severe pneumonia: implications for target-site PK/PD
基于生物标志物的美罗培南在儿童重症肺炎中的生理药动学模型构建：对靶部位药代动力学/药效学的影响
Yao Liu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf500, https://doi.org/10.1093/jac/dkaf500
40
Evaluating hypoalbuminaemia thresholds associated with delayed blood sterilization among patients receiving cefazolin or antistaphylococcal penicillins for MSSA bacteraemia
评估接受头孢唑林或抗葡萄球菌青霉素治疗甲氧西林敏感金黄色葡萄球菌（MSSA）菌血症患者中，与血液延迟灭菌相关的低白蛋白血症阈值
Sunish Shah and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf498, https://doi.org/10.1093/jac/dkaf498
Research Letters（研究快讯）
41
False-negative result in fourth-generation HIV screening tests after weak detection of p24 antigen in the context of inappropriate post-exposure prophylaxis use: a case report
不当使用暴露后预防用药导致第四代HIV筛查试验p24抗原弱检出后出现假阴性结果：一例病例报告
J Kimmerlin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf459, https://doi.org/10.1093/jac/dkaf459
42
Proposal for the nomenclature of tmexCD-toprJ-like gene clusters
关于tmexCD-toprJ样基因簇命名的建议
Chengzhen Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf482, https://doi.org/10.1093/jac/dkaf482
43
IS26-mediated chromosomal integration of virulence plasmid fragments in ST2237 carbapenem-resistant Klebsiella pneumoniae
IS26介导的毒力质粒片段在ST2237型碳青霉烯耐药肺炎克雷伯菌染色体中的整合
Yan Li and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag018, https://doi.org/10.1093/jac/dkag018
Letter to the Editor（致编辑的信）
44
Comment on: Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes
对“采用聚丙烯腈膜对接受连续性肾脏替代治疗的患者进行卡泊芬净药代动力学监测的回顾性分析”的评论
Gwénola Marais and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf465, https://doi.org/10.1093/jac/dkaf465
45
Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy-right-to-reply
意大利米兰地区使用多西环素暴露后预防（DoxyPEP）人群中，用于治疗细菌性传播感染的抗菌药物使用情况——回应说明
Angelo Roberto Raccagni and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag027, https://doi.org/10.1093/jac/dkag027
ACKNOWLEDGEMENT OF REFEREES（鸣谢审稿专家）
46
Acknowledgement of Referees
鸣谢审稿专家
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf417, https://doi.org/10.1093/jac/dkaf417
CORRECTION（更正）
47
Correction to: Comment on: Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial
更正：关于Evusheld在感染奥密克戎变异株前或奥密克戎变异株的新冠住院患者中的抗病毒效果：对随机DisCoVeRy试验的建模分析的评论
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf492, https://doi.org/10.1093/jac/dkaf492
Journal of Antimicrobial Chemotherapy Volume 81, Issue 3抗菌化疗杂志 81卷 3期
https://academic.oup.com/jac/issue
REVIEW（综述）
1
Closing the PrEP access gap in Europe: a strategic framework for equity and innovation among difficult-to-reach populations
缩小欧洲暴露前预防获取差距：面向难以触及（PrEP）人群的公平与创新战略框架
Josep M Llibre and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag052, https://doi.org/10.1093/jac/dkag052
2
Precision dosing of systemic antifungals in adults: therapeutic drug monitoring, empiric dose optimization and barriers to implementation
成人全身性抗真菌药物的精准给药：治疗药物监测、经验性剂量优化及实施障碍
Daniel B Chastain and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag055, https://doi.org/10.1093/jac/dkag055
3
Bacterial DNA topoisomerase IV and DNA gyrase inhibitors: history of the quinolones, their clinical usage and potential alternatives for the future
细菌DNA拓扑异构酶IV和DNA旋转酶抑制剂：喹诺酮类药物的历史、临床应用及未来潜在替代方案
Daisuke Fukuda and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag054, https://doi.org/10.1093/jac/dkag054
4
Combating multidrug-resistant Klebsiella pneumoniae: current therapeutic regimens and future directions
应对多重耐药肺炎克雷伯菌：当前治疗方案与未来方向
Robiul Islam and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag064, https://doi.org/10.1093/jac/dkag064
SYSTEMATIC REVIEW（系统综述）
5
Global and regional prevalence of metallo-β-lactamases in carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis
耐碳青霉烯类鲍曼不动杆菌中金属β-内酰胺酶的全球和区域流行情况：一项系统综述和荟萃分析
Stamatis Karakonstantis and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag037, https://doi.org/10.1093/jac/dkag037
Original Research（论著）
6
The effect of oral ciprofloxacin at conventional doses on the QT interval in a tertiary outpatient setting
三级门诊常规剂量口服环丙沙星对患者QT间期的影响
Weber Liu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag020, https://doi.org/10.1093/jac/dkag020
7
Bictegravir concentrations in breastmilk of healthy, lactating women without HIV
未感染人类免疫缺陷病毒（HIV）的健康哺乳期女性乳汁中的比克替拉韦浓度
L C van der Wekken-Pas and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag022, https://doi.org/10.1093/jac/dkag022
8
Management and outcomes of Stenotrophomonas maltophilia recovered from deep-site clinical specimens: a bicentric retrospective cohort study
从深部部位临床标本中分离出的嗜麦芽窄食单胞菌的治疗及转归：一项双中心回顾性队列研究
Anastasia Saade and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag021, https://doi.org/10.1093/jac/dkag021
9
Development of a risk prediction model for vancomycin-associated acute kidney injury: a multicentre retrospective study
万古霉素相关急性肾损伤风险预测模型的建立：一项多中心回顾性研究
Tomoyuki Ishigo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag012, https://doi.org/10.1093/jac/dkag012
10
Cooperation between HIV-1 integrase natural polymorphism K156N and 3′PPT mutations in dolutegravir monotherapy failure
HIV-1 整合酶天然多态性 K156N 与 3′PPT 突变在多替拉韦单药治疗失败中的协同作用
Jolieke A T van Osch and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag033, https://doi.org/10.1093/jac/dkag033
11
Impact of body mass index and serum albumin levels on isavuconazole plasma concentrations in patients with haematological malignancies
体重指数和血清白蛋白水平对血液系统恶性肿瘤患者艾沙康唑血浆浓度的影响
Jie Gao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag032, https://doi.org/10.1093/jac/dkag032
12
Pharmacokinetics of cefotaxime and its metabolite desacetyl-cefotaxime to optimize dosing in critically ill children and children with sickle cell disease
用以优化危重症儿童和镰状细胞病儿童给药剂量的头孢噻肟及其代谢产物去乙酰头孢噻肟的药代动力学研究
Seef Abdalla and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag019, https://doi.org/10.1093/jac/dkag019
13
Summary of ceftriaxone-resistant Neisseria gonorrhoeae in Canada, 2017–24
2017 - 2024年加拿大头孢曲松耐药淋病奈瑟菌情况汇总
Robyn Thorington and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag007, https://doi.org/10.1093/jac/dkag007
14
Improving perioperative prophylactic antibiotic prescribing using a novel decision-support tool
使用新型决策支持工具改进围手术期预防性抗生素处方
Mark Mcintyre and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag015, https://doi.org/10.1093/jac/dkag015
15
Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes: a multicentre study
针对产超广谱AmpC酶的阴沟肠杆菌复合群和产气克雷伯菌临床分离株，比较已上市与新一代β-内酰胺类抗生素的抗菌活性：一项多中心研究
Ángel Rodríguez-Villodres and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag034, https://doi.org/10.1093/jac/dkag034
16
Impact of eravacycline on fibrinogen
依拉环素对纤维蛋白原的影响
Emily Stevenson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag030, https://doi.org/10.1093/jac/dkag030
17
Biliary pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime–avibactam in a case series of orthotopic liver transplant recipients
原位肝移植受者连续输注头孢他啶-阿维巴坦的药代动力学/药效学胆系分析：一项病例系列研究
Milo Gatti and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag009, https://doi.org/10.1093/jac/dkag009
18
Autoaggregation-associated carbapenem tolerance mediated by mrkH inactivation identified from a cohort of Klebsiella pneumoniae species complex clinical isolates
从肺炎克雷伯菌复合群临床分离株队列中鉴定出由mrkH失活介导的与自动聚集相关的碳青霉烯耐受性
Natsuki Yamanaka and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag017, https://doi.org/10.1093/jac/dkag017
19
In vitro activity of double and triple antimicrobial combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm
双联和三联抗菌药物组合对碳青霉烯耐药铜绿假单胞菌生物膜的体外活性研究
Si-Ho Kim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag031, https://doi.org/10.1093/jac/dkag031
20
LYSC98 as a novel vancomycin-derived agent effective against antibiotic-resistant pathogens in tolerant state
LYSC98作为一种新型万古霉素衍生物，对耐受状态下的耐药病原体有效
Xing Xia and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag036, https://doi.org/10.1093/jac/dkag036
21
HBV status modulates transaminase decrease after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV
HIV感染者从富马酸替诺福韦二吡呋酯切换为丙酚替诺福韦后，HBV状态对转氨酶下降的调节作用
Giuseppe Lapadula and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag045, https://doi.org/10.1093/jac/dkag045
22
Pharmacokinetics of colistin in adult critically ill patients in South Africa
南非成人危重症患者中多黏菌素的药代动力学研究
Veshni Pillay-Fuentes Lorente and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag011, https://doi.org/10.1093/jac/dkag011
23
Antifungal susceptibility surveillance of clinical moulds to olorofim, manogepix, amphotericin B, triazoles and echinocandins at 10 tertiary hospitals in China (2019–24)
2019 - 2024年中国10家三级医院临床霉菌对奥罗芬净、马诺盖匹克斯、两性霉素B、三唑类和棘白菌素类抗真菌药的敏感性监测
Su Chen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag016, https://doi.org/10.1093/jac/dkag016
24
Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study
短周期每周三日依非韦伦/恩曲他滨/富马酸替诺福韦二吡呋酯疗法：一项为期七年的延长研究
Beatriz Borjabad and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag040, https://doi.org/10.1093/jac/dkag040
25
Risk of hypertension in people with HIV in the USA initiating modern antiretroviral regimens: pooled analysis of blood pressure data from five clinical trials
美国感染HIV者启动现代抗逆转录病毒治疗方案后患高血压的风险：五项临床试验血压数据汇总分析
Priscilla Y Hsue and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag005, https://doi.org/10.1093/jac/dkag005
26
Real-world drug monitoring of dalbavancin using a three-dose regimen of 1500mg at days 1, 15 and 43 in bone and joint or cardiovascular infection
采用第1、15和43天各1500毫克的三剂量方案对达巴万星（Dalbavancin）在骨关节或心血管感染治疗中的实际药物监测研究
Thomas Lin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag039, https://doi.org/10.1093/jac/dkag039
27
Nationwide patterns of HIV drug resistance and high viral load in Sub-Saharan African countries
撒哈拉以南非洲国家全国范围内的HIV耐药及高病毒载量模式
Abubaker Ibrahim Elbur and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf497, https://doi.org/10.1093/jac/dkaf497
28
Risk factors for suboptimal target attainment of commonly used ß-lactam antibiotics in older adults: a prospective cohort study
老年人常用β-内酰胺类抗生素未达最佳治疗目标的风险因素：一项前瞻性队列研究
Arnaud De Clercq and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag048, https://doi.org/10.1093/jac/dkag048
29
Physiologically based pharmacokinetic modelling to optimize dosing regimen of biapenem in renal impairment and elderly populations
基于生理的药代动力学模型优化肾功能不全及老年人群比阿培南给药方案
Wenyan Li and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf499, https://doi.org/10.1093/jac/dkaf499
30
Early targeted therapy guided by rapid phenotypic antimicrobial susceptibility testing in critically ill patients with Gram-negative bacterial bloodstream infections: a retrospective cohort study
快速表型抗菌药物敏感性试验指导下的早期目标性治疗对革兰氏阴性菌血流感染危重患者的效果：一项回顾性队列研究
Salvatore Rotundo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag056, https://doi.org/10.1093/jac/dkag056
31
Impact of COVID-19-related healthcare changes on antibiotic resistance in clinical Escherichia coli isolates: interrupted time series analyses in Scotland, UK
与新冠肺炎相关的医疗变化对英国苏格兰地区临床大肠杆菌分离株抗生素耐药性的影响：中断时间序列分析
Laura Ciaccio and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag049, https://doi.org/10.1093/jac/dkag049
32
Multicentre evaluation of teicoplanin prescribing and monitoring in the UK and Ireland: the TUcK–SHOP study
英国和爱尔兰替考拉宁处方与监测的多中心评估：TUcK–SHOP研究
Stephen Hughes and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag038, https://doi.org/10.1093/jac/dkag038
33
Diabetes and risk of significant fibrosis in adults with HIV and metabolic dysfunction-associated steatotic liver disease: a prospective cohort study
糖尿病与HIV合并代谢功能障碍相关脂肪性肝病成人患者发生显著肝纤维化的风险：一项前瞻性队列研究
Win Min Han and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag053, https://doi.org/10.1093/jac/dkag053
34
A pharmacovigilance analysis of carbapenem-related utilizing the FDA adverse event reporting system (FAERS) database from 2013 to 2025
基于美国食品药品监督管理局不良事件报告系统（FAERS）数据库2013 - 2025年数据的碳青霉烯类相关药物警戒分析
Connor Frey and Parham Elmi
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag060, https://doi.org/10.1093/jac/dkag060
35
Effects of extracorporeal membrane oxygenation on the pharmacokinetics and tissue penetration rates of vancomycin and linezolid: data from Landrace pigs
体外膜肺氧合对万古霉素和利奈唑胺药代动力学及组织穿透率的影响：来自长白猪的数据
Huifang Zhang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag063, https://doi.org/10.1093/jac/dkag063
36
Switching to bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and prior resistance mutations. Data from the Italian ARCA cohort: the BIC-BARRIER study. B/F/TAF switch: mutations and outcomes
在既往存在耐药突变的人类免疫缺陷病毒（HIV）感染者中换用比克替拉韦/恩曲他滨/丙酚替诺福韦治疗。来自意大利ARCA队列的数据：BIC-BARRIER研究。比克替拉韦/恩曲他滨/丙酚替诺福韦（B/F/TAF）换药方案：耐药突变与治疗结果
Laura Pezzati and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag035, https://doi.org/10.1093/jac/dkag035
37
A two-stage diagnostic model for discriminating and assessing risk of meropenem heteroresistance in Pseudomonas aeruginosa
用于鉴别和评估铜绿假单胞菌对美罗培南异质性耐药风险的二阶段诊断模型
Yali Fan and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag061, https://doi.org/10.1093/jac/dkag061
38
Microdialysis assessment of gentamicin for second-line antimicrobial prophylaxis in abdominal surgery
微透析评估庆大霉素在腹部手术中作为二线抗菌预防药物的效果
Quentin Saint-Genis and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag071, https://doi.org/10.1093/jac/dkag071
39
Genetic and clinical predictors of voriconazole pharmacokinetics and hepatotoxicity: focused on CYP2C19 normal and intermediate metabolizers
伏立康唑药代动力学及肝毒性的遗传和临床预测因素：聚焦于CYP2C19正常代谢型和中间代谢型
Hui Li and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag065, https://doi.org/10.1093/jac/dkag065
40
Stakeholder perspectives on the offer and acceptance of self-administration of outpatient parenteral antimicrobial therapy: a qualitative study
利益相关者对提供和接受门诊患者自行注射抗菌药物治疗的看法：一项定性研究
Hester H Stoorvogel and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag068, https://doi.org/10.1093/jac/dkag068
41
Is current guidance for cloxacillin prophylaxis dosages in hip and knee arthroplasty adequate? Evidence from a prospective Swedish cohort
当前髋关节和膝关节置换术中氯唑西林预防性用药剂量指南是否充分？来自一项前瞻性瑞典队列研究的证据
Katja Wallander and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag067, https://doi.org/10.1093/jac/dkag067
42
Effect of pretreatment HIV drug resistance on mortality, attrition and viral suppression in patients initiating antiretroviral therapy and genetic transmission network: an observational cohort study in Southwest China
治疗前HIV药物耐药性对开始接受抗逆转录病毒治疗患者的死亡率、失访率和病毒抑制率的影响以及遗传传播网络：中国西南地区一项观察性队列研究
Litai Qin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag073, https://doi.org/10.1093/jac/dkag073
RESEARCH LETTER（研究快讯）
43
Varicella and varicella zoster virus meningoencephalitis in a diffuse large B-cell lymphoma patient after chimeric antigen receptor-T-cell therapy
嵌合抗原受体T细胞疗法后，弥漫性大B细胞淋巴瘤患者发生水痘及水痘-带状疱疹病毒脑膜脑炎
Yan Feng and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag041, https://doi.org/10.1093/jac/dkag041
44
The ‘double hit’ on dalbavancin pharmacokinetics: hypertriglyceridaemia and augmented renal clearance in a child with glycogen storage disease type Ib
糖原累积病Ib型患儿中，高甘油三酯血症和肾清除率增加对达巴万星药代动力学的“双重打击”
Bianca Monti and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag028, https://doi.org/10.1093/jac/dkag028
45
Tn7860, a novel chromosomal pseudo-compound transposon carrying the OptrA gene in Enterococcus faecalis
Tn7860，粪肠球菌中携带OptrA基因的一种新型染色体假复合转座子
Francesca Romana Massacci and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag046, https://doi.org/10.1093/jac/dkag046
46
HBV reactivation after switching to cabotegravir plus rilpivirine therapy among people living with HIV: do not forget the reservoir
HIV感染者换用卡博特韦（cabotegravir）联合利匹韦林（rilpivirine）治疗后乙肝病毒再激活：切勿忽视病毒储存库
Rémi Rouget and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag050, https://doi.org/10.1093/jac/dkag050
47
An inoperable mediastinal infection involving vascular graft treated with weekly oritavancin as chronic suppressive therapy. A case report with pharmacokinetic data
一例涉及血管移植物的无法手术的纵隔感染，采用每周一次的奥利万星作为慢性抑制疗法。附药代动力学数据的病例报告
Pierangelo Chinello and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag013, https://doi.org/10.1093/jac/dkag013
48
Evaluation of the Carbapenemase Detection Kit (Colloidal Gold; Macro & Micro Test): a new immunochromatographic assay for rapid detection of carbapenemases in Enterobacterales
碳青霉烯酶检测试剂盒（胶体金法；宏基因与微基因检测法）评估：一种用于快速检测肠杆菌目细菌中碳青霉烯酶的新型免疫层析法
Hippolyte De Swardt and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag066, https://doi.org/10.1093/jac/dkag066
49
Cefalexin use in UK acute pyelonephritis practice: unaddressed challenges in dosing, breakpoints and clinical evidence
头孢氨苄在英国急性肾盂肾炎治疗中的应用：给药、断点和临床证据方面尚未解决的挑战
Stephen Hughes and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag051, https://doi.org/10.1093/jac/dkag051
LETTERS TO THE EDITOR（致编辑的信）
50
Comment on: Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy
评论：意大利米兰多西环素暴露后预防（DoxyPEP）使用者中用于治疗细菌性性传播感染的抗菌药物使用情况
Chris Kenyon
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag025, https://doi.org/10.1093/jac/dkag025
51
Possible increased risk of Epstein–Barr virus (EBV) infection and post-transplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients: right-to-reply
来特莫韦暴露的造血细胞移植受者发生EB病毒（EBV）感染和移植后淋巴增殖性疾病（PTLD）的风险可能增加：答复权
Jose F Camargo and Anthony D Anderson
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag043, https://doi.org/10.1093/jac/dkag043
52
Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy—right-to-reply
意大利米兰市使用多西环素暴露后预防（DoxyPEP）人群中，用于治疗细菌性性传播感染的抗菌药物使用情况——答复权声明
Angelo Roberto Raccagni and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag026, https://doi.org/10.1093/jac/dkag026
53
Comment on: Artificial intelligence for improving decision-making in bacterial infection management
述评：人工智能在细菌感染管理决策中的优化作用
Daniele Roberto Giacobbe
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag078, https://doi.org/10.1093/jac/dkag078
CORRECTION（更正）
54
Correction to: Bayesian estimation of the prevalence of antimicrobial resistance: a mathematical modelling study
更正：抗菌药物耐药性流行率的贝叶斯估计：一项数学建模研究
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf494, https://doi.org/10.1093/jac/dkaf494
55
Correction to: National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing
更正：哥伦比亚具有全国代表性的治疗前HIV耐药性调查：使用下一代测序技术分析抗逆转录病毒耐药相关突变
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag057, https://doi.org/10.1093/jac/dkag057
Journal of Antimicrobial Chemotherapy Volume 81, Issue 4抗菌化疗杂志81卷 4期
https://academic.oup.com/jac/issue
50TH ANNIVERSARY COLLECTION（50周年纪念合集）
GARROD LECTURE（加罗德讲座）
1
Garrod lecture: achieving the UNGA AMR mortality reduction goals
加罗德讲座：实现联合国大会抗菌药物耐药性死亡率降低目标
Ramanan Laxminarayan
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag082, https://doi.org/10.1093/jac/dkag082
REVIEW（综述）
2
25 years of improvement in mortality in invasive aspergillosis in haematology patients: will it be sustained or is it under threat?
侵袭性曲霉病血液病患者25年死亡率改善情况：这种改善能否持续，还是正受到威胁？
Johan A Maertens and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag077, https://doi.org/10.1093/jac/dkag077
3
A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 2: from molecule to confirmed hit
针对锥虫病的从高质量潜在客户和药物开发候选者出发的战略发现路线图。第二部分：从分子到确证活性分子
Sarah Hendrickx and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag110, https://doi.org/10.1093/jac/dkag110
VIRTUAL ROUNDTABLE（虚拟圆桌会议）
4
Diagnosis and risk factors for invasive mould disease—a round table discussion on directing antifungal therapy according to the available evidence
侵袭性霉菌病的诊断与危险因素——根据现有证据指导抗真菌治疗的圆桌讨论
Ana Alastruey-Izqueirdo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag062, https://doi.org/10.1093/jac/dkag062
EDITORIALS, MESSAGES FROM THE OUTGOING AND INCOMING EDITORS-IN-CHIEF（社论、离任与就任主编寄语）
5
Message from the incoming Editor-in-Chief of JAC
《抗菌化疗杂志》就任主编寄语
Monica A Slavin
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf479, https://doi.org/10.1093/jac/dkaf479
6
Message from the outgoing Editor-in-Chief
离任主编寄语
J Peter Donnelly
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf480, https://doi.org/10.1093/jac/dkaf480
REVIEW（综述）
7
Experimental biofilm models for pharmacokinetic and pharmacodynamic investigations: bridging in vitro, ex vivo and in vivo systems
用于药代动力学和药效学研究的实验性生物膜模型：连接体外、离体和体内系统
Stephanie Supparitsch and Markus Zeitlinger
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag091, https://doi.org/10.1093/jac/dkag091
8
Antimicrobial therapy for infected necrotizing pancreatitis: microbiology, antimicrobial resistance and pharmacokinetics
感染性坏死性胰腺炎的抗菌治疗：微生物学、抗菌药物耐药性及药代动力学
Hannah S Pauw and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag092, https://doi.org/10.1093/jac/dkag092
9
Continuous linezolid infusion: the new way to dose, the old risks to fear
持续输注利奈唑胺：新的给药方式，仍需警惕旧有风险
Daniel Muñoz-Pichuante and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag100, https://doi.org/10.1093/jac/dkag100
10
Alignment of national standard treatment guidelines with WHO AWaRe recommendations for adult primary care infectious diseases: implications for antimicrobial stewardship
将国家标准治疗指南与世卫组织（WHO）针对成人初级保健传染病的“慎用、监测、备用”（AWaRe）推荐意见相统一：对抗菌药物管理的影响
Huda Arooj and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag099, https://doi.org/10.1093/jac/dkag099
SYSTEMATIC REVIEW（系统综述）
11
Healthcare providers’ experiences in caring for MDRO carriers with a focus on the moral dimensions of care: a systematic review
医疗服务提供者护理多重耐药菌（MDRO）携带者的经历——聚焦护理中的道德维度：一项系统综述
Carlijn Damsté and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag059, https://doi.org/10.1093/jac/dkag059
12
Extrapolation of oritavancin PK/PD targets to inform therapeutic drug monitoring: a systematic review
奥利他万星药代动力学/药效学目标的外推用以指导治疗药物监测：一项系统综述
Giammarco Baiardi and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag117, https://doi.org/10.1093/jac/dkag117
ORIGINAL RESEARCH（论著）
13
Beyond plasma: defining the translation value of epithelial lining fluid exposure profiles for the treatment of pneumonia
超越血浆：明确上皮衬里液暴露谱对肺炎治疗的转化价值
Yakun Fu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf458, https://doi.org/10.1093/jac/dkaf458
14
Impact of loading dose β-lactam therapy on outcomes of KPC-producing Klebsiella pneumoniae bloodstream infections in non-ICU patients: a real world study
负荷剂量β-内酰胺类药物治疗非重症监护病房患者产KPC肺炎克雷伯菌血流感染的疗效影响：一项现实研究
Luisa Frallonardo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag087, https://doi.org/10.1093/jac/dkag087
15
Rezafungin exhibits anti-biofilm properties against fungal biofilms in vitro
雷扎芬净在体外对真菌生物膜表现出抗生物膜特性
Hafsa Abduljalil and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag058, https://doi.org/10.1093/jac/dkag058
16
Vancomycin resistance predicts increased mortality in patients with Enterococcus faecium bloodstream infections: a six-year experience at a large tertiary care Italian hospital
万古霉素耐药性可预测屎肠球菌血流感染患者死亡率增加：意大利一家大型三级医院六年来的经验
Lucia Graziani and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag069, https://doi.org/10.1093/jac/dkag069
17
Fluoroquinolones and the risk of panic attacks: a systematic review and disproportionality analysis using individual case safety reports from the FDA Adverse Event Reporting System (FAERS) database
氟喹诺酮类药物与惊恐发作风险：基于美国食品药品监督管理局不良事件报告系统（FAERS）数据库中个体病例安全报告的系统综述和比例失衡分析
Keeirah Hiertika Raguram and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag083, https://doi.org/10.1093/jac/dkag083
18
Cefuroxime concentrations in facial artery musculomucosal flap, buccal submucosa, subcutaneous tissue, and plasma following bolus or continuous infusion in patients undergoing oral cancer resection: a randomized clinical microdialysis study
在接受口腔癌切除术的患者中，采用随机临床微透析研究，探究头孢呋辛在面动脉肌黏膜瓣、颊黏膜下层、皮下组织和血浆中的浓度（团注或持续输注后）
Johanne Ravn Hansen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag085, https://doi.org/10.1093/jac/dkag085
19
Infection point of care tests bridge the experience gap of antibiotic STOP decisions: clinicians versus students
感染即时检测可弥补抗生素停药决策方面的经验差距：临床医生与学生对比
Archit Singhal and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf486, https://doi.org/10.1093/jac/dkaf486
20
Functional analysis of a novel macrolide–lincosamide resistance gene erm(57) in Cutibacterium avidum
痤疮丙酸杆菌中一种新型大环内酯 - 林可酰胺类耐药基因erm(57)的功能分析
Juri Koizumi and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag029, https://doi.org/10.1093/jac/dkag029
21
HIV drug resistance amongst children and adolescents with viraemia in Lesotho and Tanzania: a nested analysis in the GIVE MOVE trial
莱索托和坦桑尼亚病毒血症儿童及青少年中的HIV耐药性：GIVE MOVE试验的嵌套分析
Christof Manuel Schönenberger and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag070, https://doi.org/10.1093/jac/dkag070
22
Identification and assessment of paediatric cefepime-induced neurotoxicity in a retrospective cohort of paediatric intensive care patients
在儿科重症监护患者回顾性队列中识别和评估儿科头孢吡肟诱导的神经毒性
Kathryn Pavia and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag075, https://doi.org/10.1093/jac/dkag075
23
Prioritization of adverse events related to integrase inhibitors and NNRTIs: a disproportionality analysis using data from the FAERS database
整合酶抑制剂和非核苷类逆转录酶抑制剂相关不良事件的优先级排序：基于FAERS数据库数据的比例失衡分析
Gao-yang Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag074, https://doi.org/10.1093/jac/dkag074
24
Clinical and immunovirological status in children, adolescents and young adults with early-life-acquired HIV: a Spanish multi-cohort analysis since 2020
自2020年以来西班牙多队列分析中，儿童、青少年及青年时期感染HIV者的临床及免疫病毒学状态
Laura Tarancon-Diez and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag079, https://doi.org/10.1093/jac/dkag079
25
Population pharmacokinetics of meropenem in critically ill adult patients receiving extracorporeal membrane oxygenation—an ASAP ECMO study
接受体外膜肺氧合治疗的危重成年患者美罗培南的群体药代动力学——一项ASAP ECMO研究
Mohd H Abdul–Aziz and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag090, https://doi.org/10.1093/jac/dkag090
26
Evaluation of HIV-1 transmitted drug-resistance among subtypes circulating from 2022 to 2024 in Italy: a refined analysis through next-generation sequencing
2022年至2024年意大利流行HIV-1亚型间传播耐药性的评估：通过下一代测序技术进行的精细分析
Daniele Armenia and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag084, https://doi.org/10.1093/jac/dkag084
27
Characterization of efflux pump channel of florfenicol for resistance-enhancing variant RE-CmeABC in Campylobacter
耐药增强型变异体RE-CmeABC中氟苯尼考外排泵通道在弯曲菌中的特性研究
Hong Yao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag047, https://doi.org/10.1093/jac/dkag047
28
Genomic characterization of colistin heteroresistance in Acinetobacter baumannii: Evidence for lpxD deletion and collateral sensitivity
鲍曼不动杆菌中黏菌素异质性耐药的基因组特征：lpxD缺失及附带敏感性的证据
Banu Sancak and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag076, https://doi.org/10.1093/jac/dkag076
29
Sustaining stewardship: longitudinal evaluation of an integrated antimicrobial programme in the ICU
持续管理：重症监护室（ICU）综合抗菌药物管理项目的纵向评估
Ashmitha Thomas and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag086, https://doi.org/10.1093/jac/dkag086
30
Global dissemination of optrA-mediated linezolid resistance in enterococci
利奈唑胺耐药性基因optrA介导的肠球菌在全球的传播
Jia Qi Beh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag089, https://doi.org/10.1093/jac/dkag089
31
Predicting oral cephalosporin susceptibility in Escherichia coli blood isolates using parenteral cephalosporin susceptibility testing
利用肠外头孢菌素敏感性试验预测大肠杆菌血培养分离株对口服头孢菌素的敏感性
Tho H Pham and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag093, https://doi.org/10.1093/jac/dkag093
32
The pharmacodynamics of polymyxin B in Acinetobacter baumannii in murine thigh and lung infection models
在小鼠大腿和肺部感染模型中多粘菌素B对鲍曼不动杆菌的药效动力学研究
Sanne van den Berg and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag097, https://doi.org/10.1093/jac/dkag097
33
Genomic insights into the tmexCD-toprJ: plasmid-mediated evolution, dissemination and diversity in bacterial populations
关于tmexCD-toprJ的基因组见解：质粒介导的细菌群体进化、传播与多样性
Lilan Wan and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag107, https://doi.org/10.1093/jac/dkag107
34
Baseline resistance mutations and virological response to dolutegravir in treatment-naïve patients: a multicentre NGS study
初治患者基线耐药突变与多替拉韦病毒学应答：一项多中心下一代测序（NGS）研究
Alexy Inciarte and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag080, https://doi.org/10.1093/jac/dkag080
35
Novel integrase mutations linked to genotypic DTG resistance in African non-B HIV-1 strains: the DTG RESIST study
非洲非B型HIV-1毒株中与多替拉韦（DTG）基因型耐药相关的新型整合酶突变：DTG耐药研究
Nuri Han and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag088, https://doi.org/10.1093/jac/dkag088
36
Pharmacological evaluation of an ex vivo cervicovaginal HIV prevention model
体外宫颈阴道HIV预防模型的药理学评估
Lindsey B Collins and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag103, https://doi.org/10.1093/jac/dkag103
37
The magnitude of the pharmacodynamic index for NOSO-502: pathogen clearance, emergence of resistance and human dose predictions
NOSO-502药效学指数的幅度：病原体清除、耐药性出现和人体剂量预测
Sanne van den Berg and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag106, https://doi.org/10.1093/jac/dkag106
38
Temocillin: a therapeutic alternative in bone and joint infections due to third generation cephalosporin-resistant Enterobacterales?
替莫西林：治疗第三代头孢菌素耐药肠杆菌目引起的骨关节感染的一种替代疗法？
Louise Piquart and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag105, https://doi.org/10.1093/jac/dkag105
39
Metallo-β-lactamase–producing Enterobacterales: cyanide-containing efflux pump inhibitors as potential dual-activity inhibitors
产金属β-内酰胺酶的肠杆菌科细菌：含氰化物的外排泵抑制剂作为潜在的双活性抑制剂
Otávio Hallal Ferreira Raro and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag122, https://doi.org/10.1093/jac/dkag122
40
Outer membrane vesicles transmit blaNDM-5 and package metallo-β-lactamases to promote antibiotic resistance in Escherichia coli
外膜囊泡传递blaNDM-5并包装金属β-内酰胺酶以促进大肠杆菌的抗生素耐药性
Ting-Yin Lu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag123, https://doi.org/10.1093/jac/dkag123
41
Characterization of a ST412-K57 colistin-resistant hypervirulent Klebsiella pneumoniae strain of chicken origin
一株鸡源ST412-K57多粘菌素耐药高毒力肺炎克雷伯菌的特征分析
Qiu Xu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag114, https://doi.org/10.1093/jac/dkag114
42
Olorofim in combination with azole antifungals: results from the Phase 2 salvage therapy study
奥罗芬明与唑类抗真菌药联合使用：2期挽救治疗研究结果
Johan Maertens and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag118, https://doi.org/10.1093/jac/dkag118
RESEARCH LETTER（研究快讯）
43
Infant HIV transmission despite maternal viral suppression: a case of post-weaning seroconversion
母体病毒得到抑制，婴儿仍发生HIV传播：一例断奶后血清转阳病例
Shadia Nakalema and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag072, https://doi.org/10.1093/jac/dkag072
44
Urinary antigen–negative Legionella pneumonia in critically ill patients: value of systematic molecular testing for optimal antimicrobial therapy
危重患者中尿抗原阴性军团菌肺炎：系统分子检测在优化抗菌治疗中的价值
Livia Foglia Manzillo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag101, https://doi.org/10.1093/jac/dkag101
45
Contribution of SHV-1 overexpression to carbapenem resistance in a Klebsiella pneumoniae clinical isolate
SHV-1过表达对某株肺炎克雷伯菌临床分离株碳青霉烯类抗生素耐药性的影响
Céline Plainvert and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag108, https://doi.org/10.1093/jac/dkag108
LETTER TO THE EDITOR（致编辑的信）
46
Comment on: Possible increased risk of Epstein–Barr virus (EBV) infection and posttransplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients
评论：接受莱特莫韦治疗的造血细胞移植受者中，EB病毒（EBV）感染和移植后淋巴增殖性疾病（PTLD）的风险可能增加
Jan Styczynski
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag042, https://doi.org/10.1093/jac/dkag042
47
Comment on: Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis users in Milan, Italy
评论：意大利米兰地区使用多西环素暴露后预防措施人群中针对细菌性性传播感染的抗菌药物使用情况
Luca Bortolani and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag023, https://doi.org/10.1093/jac/dkag023
48
Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes—right to reply
使用聚丙烯腈膜进行连续肾脏替代治疗的患者中卡泊芬净药物治疗监测的回顾性分析——答复权
Antoine Hérault and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag095, https://doi.org/10.1093/jac/dkag095
49
Comment on: Temocillin versus other intravenous beta-lactams for urinary tract infections caused by third-generation cephalosporin-resistant Enterobacterales: a multicentre retrospective matched-cohort study
评论：替莫西林与其他静脉注射β-内酰胺类抗生素治疗第三代头孢菌素耐药肠杆菌目引起的尿路感染：一项多中心回顾性匹配队列研究
Shanshan Ru and Yingzhe Zhang
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag096, https://doi.org/10.1093/jac/dkag096
50
Comment on: Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome?
评论：长效糖肽类抗生素：对于最需要它们的患者，获取的障碍是什么，如何克服？
Marco Bongiovanni
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag102, https://doi.org/10.1093/jac/dkag102
51
Comment on ‘Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes’
评论：“对使用聚丙烯腈膜进行连续肾脏替代治疗的患者中卡泊芬净的药理学治疗监测的回顾性分析”
Julien Massol and Frédéric Baud
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag094, https://doi.org/10.1093/jac/dkag094
52
Comment on: ‘Epidemiology and treatment of endocarditis secondary to Enterobacterales other than Serratia spp’
对“除塞拉蒂亚属（Serratia spp）外肠杆菌目所致心内膜炎的流行病学和治疗”的评论
Gianpiero Tebano and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag098, https://doi.org/10.1093/jac/dkag098
53
‘Comparing serotype coverage of pneumococcal vaccines with PCV21 (V116), a new 21-valent conjugate pneumococcal vaccine, and the epidemiology of its eight unique Streptococcus pneumoniae serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) causing invasive pneumococcal disease in adult patients in Canada: SAVE study, 2018–2021-right-to-reply’
“比较肺炎球菌疫苗的血清型覆盖率——PCV21（V116，一种新型21价结合肺炎球菌疫苗）与加拿大成人患者中导致侵袭性肺炎球菌疾病的其8种独特肺炎链球菌血清型（15A、15C、16F、23A、23B、24F、31和35B）的流行病学：SAVE研究，2018 - 2021年——回应”
John J Schellenberg and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag126, https://doi.org/10.1093/jac/dkag126
54
Comment on: Antagonistic in vitro interaction between olorofim and voriconazole against Aspergillus fumigatus
评论：奥罗芬明与伏立康唑对烟曲霉的体外拮抗作用
Corinne Pinder and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag119, https://doi.org/10.1093/jac/dkag119
55
Epidemiology and treatment of endocarditis secondary to Enterobacterales other than Serratia spp.: right-to-reply
除塞氏杆菌属外肠杆菌科细菌所致心内膜炎的流行病学和治疗：回应
Sunish Shah and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag121, https://doi.org/10.1093/jac/dkag121
2026-03-29
·雪球
百花医药：2025年公司实现营业总收入3.88亿元，同比增长0.66%；归母净利润4068.79万元，同比下降1.91%；扣非净利润3278.58万元，同比增长10.57%。东瑞制药：2025年集团取得收入12.31亿元，同比增长16.1%;母公司拥有人应占溢利2.14亿元，同比减少62.1%。国邦医药：2025年公司实现营业总收入60.11亿元，同比增长2.05%；归母净利润8.21亿元，同比增长5.02%；扣非净利润7.7亿元，同比增长1.11%。国药现代:2025年公司实现营收93.63亿元，同比下降14.39%;归母净利润9.42亿元，同比下降13.11%;扣非净利润8.49亿元，同比下降18.60%;基本每股收益0.7021元。公司拟向全体股东每10股派发现金红利2元。华东医药：参股公司重庆誉颜制药有限公司自主研发的注射用重组A型肉毒毒素芮妥欣获得国家药监局批准上市，用于暂时性改善65岁及65岁以下成人因皱眉肌和/或降眉间肌活动引起的中度至重度眉间纹。华海药业：公司下属控股子公司上海华奥泰生物药业股份有限公司与Almirall，S.A.于2026年3月26日签署了全球研究合作及许可协议，用于开发具有多种潜在适应症（包括医学皮肤科）的新靶点的单克隆抗体候选药物。根据协议，华奥泰拥有在中国开发和商业化项目和产品的权利，ALM拥有在中国以外的全球开发和商业化的权利。ALM将向华奥泰支付总额不超过3.4亿美元的首付款，开发和商业化里程碑付款，以及相应的分级特许权使用费。华控康泰：2025年公司收入9.15亿港元，同比增长1.92%;公司股东应占亏损4.28亿港元，同比扩大466.41%。华兰生物：公司2025年实现营业收入45.95亿元，较上年增加4.93%；实现归属净利润9.4亿元，较上年下降13.55%。华兰生物：公司拟转让所持控股子公司华兰生物工程（苏州）有限公司75%股权，本次股权转让对价为96,714,075元，受让方为江苏康裕投资合伙企业（有限合伙）。本次交易完成后，公司将不再持有苏州公司股权，苏州公司不再纳入公司合并财务报表范围。基蛋生物：公司董事会近日收到证券事务代表王娇女士递交的书面辞职报告。王娇女士因个人原因申请辞去公司证券事务代表职务，辞职后不再担任公司任何职务。金嗓子：2025年集团取得收益9.43亿元，同比减少20.4%;母公司拥有人应占溢利2.51亿元，同比减少21.16%。巨星医疗控股：2025年持续经营业务收益约14.9亿元，同比减少38.17%;公司拥有人应占亏损7503万元，同比盈转亏。君圣泰医药-B:2025年公司亏损为2.32亿元，相比于去年亏损3.82亿元有所减少；录得其他收入约1900万元，较去年减少72.1%，主要由于政府补助减少约2980万元及金融资产的其他投资收益减少约990万元。康沣生物-B：2025年集团取得收入9526.8万元，同比增加78%;年内亏损4445.6万元，同比收窄60%。康健国际医疗：2025年集团录得溢利约6480万港元，其中包括公司拥有人应占溢利约1437.7万港元。董事会建议派付本年度的末期股息每股0.18港仙。联康生物科技集团：2025年集团取得收益5.86亿港元，同比增加6%;年内溢利9332.7万港元，同比增加12.7%。美中嘉和：2025年公司收入4.6亿元，同比增长18.4%;公司拥有人应占亏损2.57亿元，同比收窄42.1%。欧普康视：公司2025年度实现营业收入18.61亿元，较上年同期增长2.62%，实现归属于上市公司股东的净利润4.8亿元，较上年同期下降16.2%。向全体股东每10股派发现金红利1.32元。普华和顺：2025年公司收入同比上升7.1%至约8.24亿元;经调整净溢利同比下降15.4%至约1.98亿元。瑞丽医美：2025年公司总收益为1.89亿元；年内溢利为190万元。三爱健康集团：2025年预期公司将录得亏损介乎25.5百万元至27.5百万元，而2024年同期则录得溢利约3.4百万元。圣诺医药-B：公司在2025年未产生任何收益，而2024年则有178万美元的许可收入。年内亏损由2024年的5025万美元减少至1461万美元，主要得益于行政开支和研发开支的显著降低，行政开支由1720万美元降至500万美元，研发开支则由2080万美元降至1030万美元。石四药集团：2025年集团在需求收缩、政策深化与行业竞争加剧的多重压力下，主要经济指标承受了前所未有的下行压力，销售收入约为38.12亿元人民币，同比减少27.6%；毛利率约为41.6%，同比下降8.8个百分点；净利润约为4.71亿港元，同比减少55.6%。石四药集团：本集团已取得中国国家药品监督管理局有关乳酸钠林格冲洗液(3000ml)和布美他尼注射液(2ml:1mg)的药品生产注册批件，均属于化学药品第3类，视同通过一致性评价。太极集团：2025年公司实现营业收入105.00亿元，同比下滑15.23%；归母净利润1.21亿元，同比增长352.38%；扣非归母净利润4367.17万元，同比增长13.32%。天坛生物：2025年公司实现营收61.68亿元，同比增长2.26%;归母净利润10.91亿元，同比下降29.59%;扣非净利润10.76亿元，同比下降29.13%;基本每股收益0.55元。公司拟向全体股东每股派发现金红利0.05元。威高股份：2025年公司取得营业收入15.39亿元，同比增长5.95%;归属于母公司所有者的净利润2.67亿元，同比增长19.17%。威高股份：于2026年3月27日，本公司与威高生物签订土地使用权转让协议，威高生物同意以代价人民币3970.93万元转让该土地的土地使用权予本公司。威高血净：公司2025年实现营业收入37.69亿元，同比增长4.57%；归属净利润4.82亿元，同比增长7.33%。公司拟每10股派发现金红利3.608元。沃森生物:2025年公司实现营业总收入24.18亿元，同比下降14.29%；归母净利润1.78亿元，同比增长25.03%。希玛医疗：公司2025年的收益为19.47亿港元，同比增长1.8%；毛利为6.04亿港元，同比增长14.4%；归母净利润为1亿港元，较2024年的亏损1.35亿港元实现扭亏为盈。讯飞医疗科技：2025年公司去年实现营收9.15亿元，同比增长24.7%；年内亏损6577万元，同比亏损大幅收窄益佰制药：公司近日获国家药监局核准签发注射用阿扎胞苷《药品注册证书》，规格100mg，视同通过一致性评价，适用于中高危骨髓增生异常综合征等血液肿瘤，累计研发投入1893.41万元。盈康生命：2025年公司营收规模与盈利水平实现双提升，实现营业收入18.86亿元，同比增长20.93%；实现归属于上市公司股东的净利润6,854.07万元，同比下降40.62%，主要系圣诺医疗达成收购时承诺的业绩目标，交易对价调增所致，属于一次性非经常性事项，剔除以上主要事项影响，实现归属于上市公司股东的扣除非经常性损益的净利润10,713.23万元，同比增长28.50%。愉悦集团：2025年集团取得收益2828.2万元，同比增加11.53%;公司拥有人应占亏损500.6万元，同比扩大20.39%。再鼎医药：2025年公司产品收入净额增加15%至4.57亿美元，主要是由于鼎优乐的销售增加（得益于强劲的患者需求和医院覆盖范围的持续扩大，惟受到本年内供应限制的部分影响）及纽再乐的销售增加（得益于市场覆盖率和渗透率的提升）。亏损净额减少32%至1.76亿美元，主要是由于产品收入增长快于净营运开支及汇兑损失转为汇兑收益，但被利息收益减少所抵销。中国同辐：2025年集团取得收益71.88亿元，同比减少5.11%;公司权益股东应占利润3.27亿元，同比减少19.48%;每股盈利1.02元，拟派发末期现金股息每股0.2264元。营业收入下降主要受甲类大型医疗装备集采延迟导致核医疗装备收入下降影响。中国智能健康：2025年集团取得收入9956.4万港元，同比减少12.34%;本公司拥有人应占年内亏损260.6万港元，同比收窄93.53%。
财报高管变更引进/卖出
2026-03-29
盟科药业（688373）财报分析报告
报告日期：2026-03-281. 公司与业务一句话定位
盟科药业是一家以小分子化药研发为核心、聚焦抗耐药菌感染领域的科创板创新药企业，目前仅有一款商业化产品（康替唑胺片），处于依靠IPO募资和银行贷款支撑研发的亏损期。主营业务构成
公司收入来源极度集中。2025年全部营业收入1.42亿元（同比+8.83%），100%来自康替唑胺片（商品名”优喜泰”）的境内销售。毛利率84.80%，较上年提升2个百分点。无海外收入、无其他产品收入。
年度
营业收入（亿元）
同比增速
毛利率
2021
0.08
–
92.45%
2022
0.48
+500%+
81.70%
2023
0.91
+89.6%
81.61%
2024
1.30
+43.5%
82.80%
2025
1.42
+8.83%
84.80%
2025年收入增速从前两年的43%-90%区间骤降至8.83%，公司解释为商业化模式正处于从自建团队向”自建+第三方”双轮驱动的过渡阶段，第三方合作主要在Q4完成，对当期增量贡献有限。产品/服务详解
康替唑胺片（MRX-1）：公司自主设计的新一代噁唑烷酮类抗菌药，2021年6月获批上市。适应症为复杂性皮肤和软组织感染（cSSTI），靶向多重耐药革兰阳性菌（MRSA、VRE、MRCNS）。核心卖点是相比同类药物利奈唑胺，在保持疗效的同时安全性更优——减少骨髓抑制和单胺氧化酶抑制等不良反应。已纳入国家医保目录（乙类），2025年12月以原价续约进入第三个协议期。截至2025年末覆盖703家医院，正式准入及批量临采220家。
在研管线（4款临床阶段+多款临床前）：
产品
类型
适应症
最新进度
MRX-4
康替唑胺前药（注射剂）
cSSTI / 糖尿病足感染 / 耐药G+菌感染
cSSTI中国NDA已受理；糖尿病足III期全球入组541例；耐药G+菌中国III期启动26中心
MRX-5
苯并硼唑类口服抗生素
非结核分枝杆菌（NTM）感染
中国I期完成健康受试者研究；美国IND获批，IIa期待开展
MRX-8
新一代多黏菌素类注射剂
多重耐药革兰阴性菌感染
中美I期均完成
康替唑胺片（儿童）
已上市药物适应症拓展
儿童cSSTI
中国II期进行中，入组24例
此外，公司正向非感染领域拓展：ADC（MRX-23，双抗ADC靶向实体瘤）、多肽药物偶联物（MRX-17，肾脏靶向）、PROTAC（MRX-27，STAT6降解）、分子胶（MRX-29，NEK7），均处于临床前。商业模式
公司采用MAH（药品上市许可持有人）模式，自身不拥有生产设施，委托第三方进行原料药和制剂生产。营业成本中，委托加工费用占65%，直接材料占31%。这种”轻资产”模式降低了固定资产投入，但也意味着对上游供应商的依赖——第一大供应商采购额占年度采购总额的46.37%。
销售端，2025年进行了模式升级：从纯自建团队转向”自建学术推广团队+第三方学术推广团队”双轮驱动。自建团队专注核心市场和重点医院的学术推广，第三方团队快速扩大覆盖面。产品通过医药商业经销商配送至医院和药店，医院渠道销售占比约76%，药店渠道占比约24%。
现金流模式：经营活动持续净流出（2025年-2.1亿元），靠消耗IPO募集资金中购买的理财产品（交易性金融资产从上市初的11.19亿逐年赎回至1.36亿）和银行贷款维持运转。客户与供应商
客户：前五大客户占年度销售总额的91.42%，客户集中度极高。客户均为医药商业经销商，不存在关联关系。客户五为2025年新进入前5名。
供应商：前五大供应商占年度采购总额的70.41%，其中第一大供应商占比46.37%。第一大供应商为委托生产合作方，依赖度显著。供应商四、五为本期新进入。业务演进与战略方向
2021-2022年：完成IPO融资（募资约9.82亿元），康替唑胺片上市并纳入医保，进入商业化早期阶段，收入规模从0.08亿快速增长至0.48亿。研发管线以MRX-4为核心推进。
2023-2024年：商业化加速，收入从0.91亿增至1.30亿。研发投入维持高位（2024年3.69亿，为当年收入的2.83倍），多条管线同时推进III期和I期临床。但总资产从14.97亿持续下降至8.49亿，IPO募资快速消耗。
2025年：出现战略拐点。一方面，公司主动压缩费用——研发投入从3.69亿降至2.14亿（-42%），销售费用从1.10亿降至0.90亿（-18%），亏损从4.41亿收窄至2.42亿。另一方面，商业化模式升级至2.0版本，引入第三方推广团队。MRX-4中国NDA获受理，MRX-5获美国IND批准。同时，公司开始布局非感染领域（ADC、PROTAC、分子胶），战略从”纯抗感染”转向”感染为主+非感染拓展”。
管理层明确了2026年经营重点：推动MRX-4获批上市，借助外部渠道资源加速康替唑胺片放量，同时推进MRX-5美国IIa期临床。2. 行业分析行业概况
盟科药业所处的细分领域是抗耐药菌感染创新药。在全球层面，抗菌药物耐药性（AMR）被WHO列为对全球卫生的最大威胁之一。据估计，到2050年AMR将造成每年1000万人死亡。但与巨大的临床需求形成鲜明对比的是，大型药企普遍撤出抗菌药研发（阿斯利康2015年撤出、诺华2019年停止、赛诺菲放弃），原因是市场上已有抗菌药以低价形成新药进入壁垒，投资回报率偏低。
市场规模：根据2025年年报引用的弗若斯特沙利文数据：
• 中国多重耐药革兰阳性菌（MDR G+）抗菌药市场2025年约57亿元，其中噁唑烷酮类约11亿元（受利奈唑胺集采影响，2020-2025年复合增长率-5.0%），预计2030年噁唑烷酮类增至36亿元（CAGR 25.5%）
• 中国多重耐药革兰阴性菌（MDR G-）抗菌药市场2025年约197亿元
• 全球NTM病新发病例数趋于平稳（中国2025年约4.2万人/年）
行业驱动因素
需求端：耐药菌感染持续加重，MRSA在ICU中约44%的金黄色葡萄球菌感染由其引起，CRE检出率在部分省份超30%。老龄化加剧ICU患者群体扩大，耐药菌感染负担有进一步增长趋势。
供给端：中国2015-2025年共批准18个抗菌新药。本土企业2021年后研发和商业化能力明显增强。但抗菌药领域投资回报率偏低，全球大型药企持续撤出，新药供给主要依赖生物技术公司。
政策：国家政策明确支持创新药发展——“十五五”规划将创新药纳入新质生产力培育重点，国家医保局推出”集采非新药、新药不集采”原则保护研发利润空间，《遏制细菌耐药国家行动计划》对新型耐药菌治疗药物给予优先审评审批。
技术趋势：口服制剂优于注射（提高依从性）、窄谱优于广谱（减少耐药产生）、安全性更高的下一代药物替代传统药物。竞争格局
噁唑烷酮类：中国已上市3个原研药——利奈唑胺（辉瑞，2006年获批，已进入集采）、特地唑胺（默沙东，2019年获批）、康替唑胺（盟科药业，2021年获批）。利奈唑胺集采后价格大幅下降，处方量上升但销售额下降。康替唑胺的差异化优势在于安全性（减少骨髓抑制等不良反应），但尚未进入集采。
MDR G+整体市场：中美已有16个获批药物，包括糖肽类（万古霉素）、脂肽类（达托霉素）、四环素类（奥玛环素）等。大多数竞品为注射剂型，可口服的选择有限。
管线竞争：在MDR G+领域，中国仅有盟科MRX-4处于NDA阶段，九芝堂YB211处于II期。在MDR G-领域，多个III期管线在研（头孢吡肟+齐达巴坦、XNW4107等），MRX-8仅处于I期。行业趋势
1. 利奈唑胺集采后释放的市场空间将被新一代噁唑烷酮类（康替唑胺、特地唑胺）和其他新机制药物争夺，竞争将聚焦于安全性差异化和适应症拓展
2. 注射-口服序贯治疗模式成为趋势（如MRX-4注射→康替唑胺口服），静脉给药起效快+口服接续降低住院成本
3. 抗菌药领域投资回报率偏低可能导致新药研发持续由中小型biotech承担，资金压力是常态
4. 医保政策对创新抗菌药持续友好，但具体价格谈判和市场准入仍是关键变量
本行业分析框架
基于以上行业特性，后续章节应重点关注：
• 核心竞争力：研发管线深度与临床推进能力——在抗耐药菌这个资金密集、周期漫长的领域，能否持续推进多条管线至获批上市决定公司的长期价值；产品的安全性和有效性差异化数据是市场竞争的核心武器
• 财务关键指标：现金消耗速度（Cash Burn Rate）与资金续航能力——公司处于亏损期，核心问题是”钱够不够花到盈利”；研发费用率的变化趋势反映管线推进节奏；收入增速反映商业化兑现速度
• 重点风险类型：单一产品依赖风险（全部收入来自康替唑胺片）、资金链断裂风险（净资产持续下降）、临床试验失败风险（MRX-4/MRX-5/MRX-8）、竞品获批冲击
3. 核心竞争力研发管线深度与临床推进能力
公司在抗耐药菌感染领域布局了从商业化到临床前的完整管线梯队：1款已上市（康替唑胺片）、2款III期（MRX-4两个适应症）、1款I期完成待II期（MRX-5）、1款I期完成待后续（MRX-8），以及多款临床前项目。
管线的核心逻辑围绕一个”同心圆”结构展开：
• 内圈：康替唑胺片及其前药MRX-4，覆盖MDR革兰阳性菌感染的口服和注射场景。MRX-4的获批将使公司拥有”静脉序贯口服”的完整治疗方案，直接对标利奈唑胺的口服+注射双剂型组合
• 中圈：MRX-5（NTM感染）和MRX-8（MDR革兰阴性菌），拓展至不同类型的耐药菌感染。MRX-5获得FDA孤儿药资格认定，在NTM治疗领域全球尚无同类抗菌药获批
• 外圈：ADC、多肽偶联物、PROTAC、分子胶等非感染领域管线，均处于早期临床前阶段
研发投入方面，2021-2025年累计研发支出约12.60亿元，全部费用化处理（不存在资本化）。2025年研发投入2.14亿元，仍为营业收入的1.51倍。研发团队69人（占公司总人数41.57%），其中博士9人、硕士30人。公司在中美两地设有研发中心，美国子公司盟科美国2025年营业收入1.17亿元（全部为内部研发服务）。
在研项目总预计投资规模约22.02亿元，截至2025年末累计投入16.54亿元，完成度约75%。其中MRX-4预计总投资9.50亿元，累计投入9.21亿元，已接近预算上限。产品的安全性差异化
康替唑胺片相对于利奈唑胺的核心差异化在于安全性。根据公司披露，康替唑胺在临床试验中显示出与利奈唑胺相当的疗效，同时在骨髓抑制、单胺氧化酶抑制等不良反应方面优于利奈唑胺。这一差异化优势通过以下方式持续强化：
• 2025年有4部指南/共识推荐康替唑胺应用（老年肺炎、噁唑烷酮类临床应用指引、耐药结核病全口服短程治疗、重症超说明书用药）
• 15项研究者发起的临床研究（IIT）在进行中，覆盖耐药结核、血流感染、中枢神经系统感染等多个领域
• 年度新增医学循证积累及学术建设成果46项
专利保护方面，2026年1月获得药品专利权期限补偿，专利权期满终止日从2028年8月延至2033年8月，为产品生命周期提供了额外5年保护。截至2025年末，公司累计拥有34项获授发明专利。竞争力评估
优势：
1. 在MDR革兰阳性菌口服抗菌药领域，康替唑胺是中国首个获批的国产原研噁唑烷酮类新药，具有先发优势
2. MRX-4若获批，将形成”注射+口服”完整治疗方案，在中国MDR G+领域管线进度领先（中国仅此一个NDA阶段产品）
3. 研发团队具有国际创新药研发经验，中美双中心运作降低了研发成本并加速了全球注册
4. 专利期限补偿为核心产品额外争取了5年保护期
薄弱环节：
1. 商业化能力尚未得到充分验证——2025年收入增速骤降至8.83%，仅71人的商业化团队覆盖703家医院，人均产出和覆盖效率有待观察
2. 除康替唑胺/MRX-4外，其他管线距离商业化尚远——MRX-5最快也需要数年才能获批，MRX-8仅完成I期，非感染领域管线全部在临床前
3. 公司无实际控制人，Genie Pharma（10.92%）为第一大股东，治理结构存在不确定性
4. 研发投入虽高，但主要集中在MRX-4一个项目（2025年占总研发投入的73.7%），管线多元化的实际深度有限
4. 财务分析行业关键指标（近5年趋势）现金消耗速度与资金续航能力
年度
经营活动现金净流出（亿元）
期末现金+理财（亿元）
有息负债（亿元）
净资产（亿元）
2021
-1.81
4.72
1.61
4.38
2022
-2.40
12.70
2.30
12.14
2023
-3.29
9.53
2.21
8.34
2024
-4.47
5.93
3.02
4.39
2025
-2.10
4.52
3.80
2.06
2022年IPO募资约9.82亿元后，公司将大量资金投入结构性存款等理财产品。此后理财产品逐年赎回用于支撑运营：交易性金融资产从2022年末的11.19亿降至2025年末的1.36亿元。
截至2025年末，公司货币资金3.16亿元+交易性金融资产1.36亿元=可用资金约4.52亿元，有息负债3.80亿元（短期借款0.25亿+一年内到期非流动负债0.81亿+长期借款2.13亿+租赁负债0.60亿）。按2025年经营活动现金净流出2.10亿元的速度，在不考虑新增融资和有息负债偿还的情况下，资金大约可支撑2年左右。
值得注意的是，2025年经营现金净流出较2024年大幅收窄（从4.47亿降至2.10亿），这主要得益于研发费用从3.69亿压降至2.14亿元。若管线推进需要恢复高强度研发投入，现金消耗速度将重新加快。研发费用率变化趋势
年度
研发费用（亿元）
研发费用率
同比变化
2021
1.52
1981%
–
2022
1.50
312%
收入快速增长稀释
2023
3.45
380%
管线推进加速
2024
3.69
283%
收入增长+研发微增
2025
2.14
151%
主动压缩研发支出
2025年研发费用率从283%大幅降至151%，降幅132个百分点。公司解释为”部分在研项目阶段性完成”和”严格控制研发费用支出”。具体来看，MRX-4研发投入1.58亿元（-36%），康替唑胺片研发投入0.26亿元（-49%），MRX-8仅0.03亿元（-64%），MRX-5为0.12亿元（-68%）。这反映的是MRX-4中国III期完成后的自然下降，同时也体现了公司在资金压力下的主动收缩。收入增速反映商业化兑现速度
年度
营业收入（亿元）
同比增速
销售量（盒）
医院覆盖数
2022
0.48
–
–
–
2023
0.91
+89.6%
47,676
–
2024
1.30
+43.5%
67,802
582
2025
1.42
+8.83%
73,206
703
2025年销售量同比增长约7.6%（400mg*20片规格），与收入增速基本匹配。医院覆盖数从582家增至703家（+20.8%），但收入增速并未同步放大，说明新覆盖医院尚未贡献有效增量，或者单院产出在下降。
2025年Q4单季收入3779万元为全年最高，显示第三方推广团队在Q4开始起效的迹象。2025年分季度收入呈逐季上升趋势（Q1: 3322万 → Q2: 3375万 → Q3: 3702万 → Q4: 3779万），节奏相对平稳。成长性与盈利能力
公司自上市以来持续亏损，但亏损幅度在2025年显著收窄：
年度
归母净利润（亿元）
扣非归母净利润（亿元）
净利率
2021
-2.26
-2.64
-2954%
2022
-2.20
-2.68
-457%
2023
-4.21
-4.54
-464%
2024
-4.41
-4.59
-338%
2025
-2.42
-2.50
-170%
2025年扣非归母净亏损2.50亿元，较2024年的4.59亿元收窄45.5%。改善主要来自费用压缩而非收入放量。
费用端结构变化：
费用项
2024年（亿元）
2025年（亿元）
变化
销售费用
1.10
0.90
-18.3%
管理费用
0.66
0.62
-5.8%
研发费用
3.69
2.14
-42.0%
财务费用
0.13
0.07
-47.7%
ROE因净资产持续缩小而持续恶化，2025年加权平均净资产收益率-75.34%，不具参考意义。财务健康度
资产负债率：从2022年末的18.91%上升至2025年末的70.85%。这一快速攀升不是因为大幅举债，而是因为净资产被持续亏损侵蚀——净资产从12.14亿降至2.06亿，降幅83%。
未分配利润：-20.46亿元，累计亏损持续扩大。股本6.56亿+资本公积15.88亿=合计22.44亿，已被累计亏损抵消大部分。
有息负债结构：2025年末有息负债3.80亿元（短期借款0.25亿+一年内到期0.81亿+长期借款2.13亿+租赁负债0.60亿），较2024年末的3.02亿增加0.78亿。其中长期借款从1.23亿增至2.13亿，增幅73%，公司正在加大银行贷款力度以补充营运资金。
现金流质量：经营活动现金流持续为负，但2025年净流出2.10亿元是上市以来最低水平（2024年为4.47亿）。销售商品收到的现金1.54亿元，覆盖营业收入的比例约109%，回款能力尚可。
境外资产：境外资产2.57亿元，占总资产的36.39%，主要为美国子公司盟科美国（总资产4.35亿元）。盟科美国2025年净亏损3204万元，为美国研发平台的运营支出。
重大科目异常：应收账款3796万元，同比增长19%，账期略有延长。期末库存70,728盒，同比增长34%，公司解释为预计2026年销量攀升而主动备货，需关注后续去化情况。5. 风险因素管理层披露的主要风险
1. 资金链断裂风险（财务风险）：公司明确警示”如果公司无法获得足够的营运资金，公司将被迫推迟、削减或取消公司的研发项目”，甚至”可能导致公司出现净资产为负的情况，届时公司甚至将面临退市风险”。这是管理层在年报中给出的最严厉警告。以2025年末净资产2.06亿元和年度亏损约2.42亿元的规模，若不能有效融资或实现收入大幅增长，净资产转负可能在2026-2027年发生。
2. 单一产品依赖风险（经营风险）：全部收入来自康替唑胺片一款产品，MRX-4即便获批也需要时间放量。管理层表示”公司的短期经营业绩将受到单一产品的限制，面临单一产品依赖的市场风险”。
3. 临床试验失败风险（经营风险）：MRX-4糖尿病足感染全球III期、MRX-4耐药G+菌中国III期、MRX-5 IIa期等关键临床试验均存在失败可能。MRX-4预计总投资9.5亿元已投入9.21亿元，若临床失败将导致”财务资源的重大损失”。
4. 无实际控制人风险（治理风险）：公司没有控股股东和实际控制人，第一大股东Genie Pharma持股仅10.92%。管理层坦承这”可能导致公司治理格局的不稳定或决策效率低下”，也存在敌意收购风险。
风险变化
新增风险（对比2024年年报）：
• 2025年年报新增了”宏观环境风险”中关于”地缘政治”的表述，2024年年报仅提及”药品监管政策、知识产权保护法规和贸易壁垒”。这反映了中美关系变化对公司跨国运营模式的潜在影响
• 公司2025年新设4家境内子公司（喜瑞诚泰、康粤生物、科迈生物、沪盟诚泰），主要用于各区域的药品批发和推广，这与第三方商业化模式升级相关，可能带来管理复杂度上升
改善信号：
• 2025年研发投入大幅降至2.14亿元（-42%），亏损收窄至2.42亿元，经营现金流净流出收窄至2.10亿元，烧钱速度明显放缓
• 康替唑胺片专利保护期延至2033年8月，消除了2028年专利到期后仿制药冲击的近期担忧
• MRX-4中国NDA获受理，若2026年获批将是重要里程碑
隐含风险
1. IPO理财池见底：交易性金融资产从2022年末的11.19亿降至2025年末的1.36亿元，这一”缓冲垫”几乎耗尽。此前公司靠赎回理财产品弥补经营现金缺口的模式不可持续，2026年起必须更多依赖银行贷款或股权融资。
2. 商业化团队收缩的矛盾信号：2025年末商业化团队71人，较2024年末的86人减少了15人（-17.4%），同期医院覆盖数反而从582家增至703家。团队缩减+覆盖扩大+增速骤降的组合，暗示自建团队的效能可能在下降，向第三方模式转型能否补上缺口尚待验证。
3. 美国子公司的持续亏损：盟科美国2025年净亏损3204万元，作为美国研发平台持续消耗资金。在中美关系不确定性增加的背景下，这部分海外投入的回报周期和政策风险需要关注。
4. 库存快速增长：2025年末库存70,728盒，同比+34%，但同期销售量仅增长7.6%。备货对2026年销量增长有乐观预期，若实际销售不及预期，将出现减值压力。
5. 费用压缩的可持续性存疑：2025年通过大幅压缩研发和销售费用实现了亏损收窄，但管线推进（MRX-5美国IIa期、MRX-4全球III期）需要持续投入。费用压缩更多是短期的财务优化而非结构性改善。
后续跟踪重点
基于本次分析，持续跟踪应优先关注：
1. MRX-4中国NDA审评进展 → 验证信号：国家药监局审评意见、是否需要补充资料、预期获批时间。MRX-4获批是公司从”单一产品”向”口服+注射组合”升级的关键节点，直接影响收入增长和市场估值。
2. 2026年康替唑胺片季度销售趋势 → 验证信号：季度收入增速是否恢复至20%+水平、第三方推广团队贡献的增量占比。2025年增速骤降至8.83%是暂时的过渡现象还是增长瓶颈，需要至少2-3个季度的数据验证。
3. 资金续航能力与融资动作 → 验证信号：新增银行授信、是否启动定增/可转债/海外融资。净资产2.06亿元、年亏损2.42亿元的组合使得净资产转负可能在2026-2027年出现，这是最迫切的生存问题。
4. MRX-5美国IIa期临床启动与进展 → 验证信号：首例患者入组时间、FDA反馈。MRX-5在NTM领域获得FDA孤儿药认定，若IIa期数据积极，有望打开海外合作（license-out）或融资渠道。
5. 商业化模式升级效果 → 信息来源建议：关注半年报中商业化团队人数、医院覆盖数、正式准入医院数、渠道占比变化。重点观察第三方推广团队是否带来可量化的增量。
免责声明：本报告由 Insight 分析系统生成，仅供个人学习和研究参考，不构成任何投资建议。报告内容基于公开披露信息整理，不保证准确性和完整性。作者可能持有报告中提及的证券。投资有风险，决策需谨慎。
100 项与 甲苯磺酸奥马环素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 社区获得性细菌性肺炎 | 美国 | 2018-10-02 | |
| 皮肤和皮肤结构感染 | 美国 | 2018-10-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 蜂窝织炎 | 临床3期 | 中国 | 2019-03-01 | |
| 蜂窝织炎 | 临床3期 | 中国 | 2019-03-01 | |
| 丹毒 | 临床3期 | 中国 | 2019-03-01 | |
| 丹毒 | 临床3期 | 中国 | 2019-03-01 | |
| 社区获得性肺炎 | 临床3期 | 格鲁吉亚 | 2015-11-22 | |
| 简单的皮肤和皮肤结构感染(uSSSI) | 临床3期 | - | 2009-07-01 | |
| 皮肤结构和软组织感染 | 临床3期 | - | 2009-07-01 | |
| 复杂皮肤和皮肤结构感染 | 临床3期 | 美国 | 2009-04-04 | |
| 复杂皮肤和皮肤结构感染 | 临床3期 | 美国 | 2009-04-04 | |
| 传染性皮肤病 | 临床3期 | 美国 | 2009-04-04 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床1期 | 23 | (Adolescents, Cohort 1: 100 mg IV Omadacycline) | 繭獵鏇鏇觸觸糧遞齋鏇(構積餘網廠淵構蓋鏇顧) = 範淵醖鏇製餘願艱構襯 襯願廠窪簾鏇齋廠淵醖 (選膚簾鑰簾醖醖願鏇襯, 27.3) 更多 | - | 2026-03-09 | ||
(Children, Cohort 2: 100 mg IV Omadacycline) | 繭獵鏇鏇觸觸糧遞齋鏇(構積餘網廠淵構蓋鏇顧) = 襯鑰積選鏇簾簾窪遞淵 襯願廠窪簾鏇齋廠淵醖 (選膚簾鑰簾醖醖願鏇襯, 40.1) 更多 | ||||||
临床2期 | 66 | (Omadacycline 300 mg) | 夢繭願築網製觸願窪積 = 觸鹹衊構鬱觸醖觸鹽願 鬱製鹽憲觸鏇淵簾築觸 (鹽積糧蓋壓淵艱顧繭製, 窪獵夢廠襯淵衊積餘願 ~ 艱網構膚餘憲淵壓願淵) 更多 | - | 2025-07-30 | ||
placebo (Placebo) | 夢繭願築網製觸願窪積 = 積齋鑰蓋積憲膚製膚觸 鬱製鹽憲觸鏇淵簾築觸 (鹽積糧蓋壓淵艱顧繭製, 衊糧觸衊廠構獵網觸鏇 ~ 淵顧願簾鬱選衊淵遞艱) 更多 | ||||||
临床2期 | - | 鬱築範構選獵鹽壓夢範(鑰衊憲簾夢糧鏇壓糧鬱) = 蓋簾積範憲淵壓齋構鑰 廠糧襯餘衊糧衊鏇鬱糧 (繭繭蓋積窪醖糧積繭齋 ) | 积极 | 2025-05-16 | |||
Placebo | 鬱築範構選獵鹽壓夢範(鑰衊憲簾夢糧鏇壓糧鬱) = 齋顧淵遞壓夢遞簾繭繭 廠糧襯餘衊糧衊鏇鬱糧 (繭繭蓋積窪醖糧積繭齋 ) | ||||||
临床3期 | 670 | (Omadacycline) | 窪壓艱繭襯構願繭鹹積 = 簾簾構廠壓醖壓鬱鹹遞 築繭鑰繭顧淵繭遞觸網 (網願獵築獵獵糧壓願鏇, 顧餘顧願獵淵憲蓋鹽鬱 ~ 鏇繭鹽壓窪壓憲鬱選餘) 更多 | - | 2025-04-09 | ||
(Moxifloxacin) | 窪壓艱繭襯構願繭鹹積 = 鹽襯鬱廠範蓋築鬱鹽構 築繭鑰繭顧淵繭遞觸網 (網願獵築獵獵糧壓願鏇, 築衊壓齋繭鑰選選醖艱 ~ 範遞襯齋憲鹹鏇衊壓窪) 更多 | ||||||
临床4期 | - | 8 | 選遞顧構餘廠簾淵築製(願網鬱構齋鑰願鏇繭醖) = 齋壓觸遞鏇網壓構網夢 窪膚膚襯網夢鬱構廠顧 (範廠衊網憲構構範蓋壓, 0.0622) 更多 | - | 2025-03-17 | ||
临床4期 | 9 | 鏇壓淵壓顧獵艱齋範鏇(選願壓窪築齋製構壓鑰) = 衊範夢淵壓獵鏇繭遞選 壓選糧顧夢鑰網獵觸蓋 (築憲觸餘憲淵獵獵積網 ) | 积极 | 2024-12-01 | |||
鏇壓淵壓顧獵艱齋範鏇(選願壓窪築齋製構壓鑰) = 鹹簾簾鏇淵範廠齋淵淵 壓選糧顧夢鑰網獵觸蓋 (築憲觸餘憲淵獵獵積網 ) | |||||||
临床2期 | 66 | 網築鹽鑰鏇齋壓夢糧網(範願積顧餘範築鏇膚積) = 網艱齋鏇齋淵築襯壓鹹 鏇膚艱淵鹽餘遞積鬱齋 (鏇艱窪膚窪範餘齋膚積 ) 更多 | 积极 | 2024-11-08 | |||
Placebo | 網築鹽鑰鏇齋壓夢糧網(範願積顧餘範築鏇膚積) = 餘衊餘顧廠淵鬱餘廠遞 鏇膚艱淵鹽餘遞積鬱齋 (鏇艱窪膚窪範餘齋膚積 ) 更多 | ||||||
临床3期 | - | 鏇構鑰鏇鹽鏇醖鏇製糧(衊遞鏇襯鹹餘鹽壓襯繭) = 範鹹築鹽鏇窪鏇廠觸襯 觸鹽膚願淵鏇壓齋鬱膚 (醖襯齋選蓋鹽遞鑰鹽襯 ) 更多 | 积极 | 2024-10-26 | |||
鏇構鑰鏇鹽鏇醖鏇製糧(衊遞鏇襯鹹餘鹽壓襯繭) = 構網醖醖積鬱壓構觸淵 觸鹽膚願淵鏇壓齋鬱膚 (醖襯齋選蓋鹽遞鑰鹽襯 ) 更多 | |||||||
GlobeNewswire 人工标引  | 批准上市 | 670 | NUZYRA® (omadacycline) | 積遞鹽壓繭廠鏇憲壓簾(構繭製壓餘鹽襯齋壓壓) = 夢簾製製壓製憲鹹廠襯 鹽糧糧構鬱顧衊夢獵窪 (蓋觸醖夢醖糧鏇鬱蓋夢 ) 达到 更多 | 积极 | 2024-07-18 | |
積遞鹽壓繭廠鏇憲壓簾(構繭製壓餘鹽襯齋壓壓) = 鹽衊製衊蓋簾選襯窪鑰 鹽糧糧構鬱顧衊夢獵窪 (蓋觸醖夢醖糧鏇鬱蓋夢 ) 达到 更多 | |||||||
N/A | - | 鏇艱淵齋構夢憲艱繭鹽(廠鏇築衊膚衊繭廠壓選) = 齋鬱網獵範顧鏇艱壓膚 壓壓鏇遞鏇鏇選餘艱鏇 (築觸鹹構顧簾襯獵齋鹹 ) 更多 | 积极 | 2024-03-05 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用